Oncotelic Therapeutics (OTLC) 10-Q 16 Nov 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Nov. 11, 2020
Cover [Abstract]
Entity Registrant Name	MATEON THERAPEUTICS INC
Entity Central Index Key	0000908259
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		89,601,912
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash	$ 1,362,188	$ 81,964
Restricted cash	20,000
Accounts receivable	19,748	149,748
Prepaid & other current assets	88,010	41,288
Total current assets	1,489,946	273,000
Development equipment, net of depreciation of $83,152 and $64,404	19,477	47,554
Intangibles, net of accumulated amortization of $124,133 and $85,608	886,047	924,572
In process R&D, net of accumulated amortization of $206,580 and $0	1,170,620	1,377,200
Goodwill	21,062,455	21,062,455
Total assets	24,628,545	23,684,781
Current liabilities:
Accounts payable and accrued liabilities	2,731,620	2,054,983
Accounts payable to related party	385,002	601,682
Contingent consideration	2,625,000	2,625,000
Derivative liability on Notes	776,470	540,517
Convertible debt, net of costs	1,017,868	944,450
Convertible debt, related party, net of costs	330,674	16,474
Private placement convertible debt, net of costs	612,892
Private placement convertible debt, related party, net of costs	33,274
Payroll Protection Plan loan	251,104
Total current liabilities	8,763,904	6,783,106
Commitments and contingencies (Note 11)
Stockholders' equity:
Convertible Preferred stock, $0.01 par value, 15,000,000 shares authorized; 278,188 and 278,188 shares issued and outstanding	2,782	2,782
Common stock, $.01 par value; 150,000,000 shares authorized; 89,601,912 and 84,069,967 issued and outstanding, respectively	896,020	840,700
Additional paid-in capital	32,176,064	28,185,599
Accumulated deficit	(18,189,766)	(12,127,406)
Total Mateon Therapeutics, Inc stockholders' equity	14,885,100	16,901,675
Non-controlling interest	979,541
Total stockholders' equity	15,864,641	16,901,675
Total liabilities and stockholders' equity	$ 24,628,545	$ 23,684,781

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Depreciation of development equipment	$ 83,152	$ 64,404
Amortization of intangible assets	$ 124,133	$ 85,608
Convertible Preferred stock, par value	$ 0.01	$ 0.01
Convertible Preferred stock, shares authorized	15,000,000	15,000,000
Convertible Preferred stock, shares issued	278,188	278,188
Convertible Preferred stock, shares outstanding	278,188	278,188
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	89,601,912	84,069,967
Common stock, shares outstanding	89,601,912	84,069,967
In Process Research and Development [Member]
Amortization of intangible assets	$ 206,580	$ 0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Service Revenue			$ 1,740,855
Operating expenses:
Research and development	936,196	343,789	1,730,337	1,109,050
General and administrative	680,077	586,924	4,263,265	1,958,731
Total operating expenses	1,616,273	930,713	5,993,602	3,067,781
Loss from operations	(1,616,273)	(930,713)	(4,252,747)	(3,067,781)
Other expense:
Interest expense, net	(331,459)	(60,413)	(1,615,233)	(88,518)
Change in fair value of derivative on debt	49,992		60,504
Loss on debt conversion	(88,817)		(254,884)
Total other expense	(370,284)	(60,413)	(1,809,612)	(88,518)
Net Loss	$ (1,986,557)	$ (991,126)	$ (6,062,360)	$ (3,156,299)
Basic & diluted net loss per share attributable to common stock	$ (0.02)	$ (0.01)	$ (0.07)	$ (0.06)
Basic & diluted weighted average common stock outstanding	88,964,549	74,526,579	87,474,986	52,131,543

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Non-Controlling Interest [Member]	Total
Balance at Dec. 31, 2018		$ 68,438	$ 7,886,598	$ (5,490,277)		$ 2,464,759
Balance, shares at Dec. 31, 2018		6,843,802
Common shares issued for cash		$ 208	82,792			83,000
Common shares issued for cash, shares		20,750
Common shares issued for services		$ 918	417,218			418,136
Common shares issued for services, shares		91,844
Stock-based compensation			268,259			268,259
Common shares issued for settlement of accounts payable to related party		$ 808	237,282			238,090
Common shares issued for settlement of accounts payable to related party, shares		80,772
Net loss				(976,063)		(976,063)
Balance at Mar. 31, 2019		$ 70,372	8,892,149	(6,466,340)		2,496,181
Balance, shares at Mar. 31, 2019		7,037,168
Balance at Dec. 31, 2018		$ 68,438	7,886,598	(5,490,277)		2,464,759
Balance, shares at Dec. 31, 2018		6,843,802
Net loss						(3,156,299)
Balance at Sep. 30, 2019	$ 1,937	$ 834,700	12,609,430	(8,645,695)		4,800,372
Balance, shares at Sep. 30, 2019	193,713	83,469,966
Balance at Mar. 31, 2019		$ 70,372	8,892,149	(6,466,340)		2,496,181
Balance, shares at Mar. 31, 2019		7,037,168
Stock-based compensation			72,415			72,415
Recapitalization under reverse merger	$ 1,937	$ 752,328	2,972,606	881		3,727,752
Recapitalization under reverse merger, shares	193,713	75,232,798
Beneficial Conversion Feature on convertible debt and restricted common shares		$ 10,500	498,640			509,140
Beneficial Conversion Feature on convertible debt and restricted common shares, shares		1,050,000
Common shares issued in conversion of warrants		$ 1,500	(1,380)			120
Common shares issued in conversion of warrants, shares		150,000
Net loss				(1,189,110)		(1,189,110)
Balance at Jun. 30, 2019	$ 1,937	$ 834,700	12,434,430	(7,654,569)		5,616,498
Balance, shares at Jun. 30, 2019	193,713	83,469,966
Beneficial conversion feature on convertible debt			175,000			175,000
Net loss				(991,126)		(991,126)
Balance at Sep. 30, 2019	$ 1,937	$ 834,700	12,609,430	(8,645,695)		4,800,372
Balance, shares at Sep. 30, 2019	193,713	83,469,966
Balance at Dec. 31, 2019	$ 2,782	$ 840,700	28,185,599	(12,127,406)		16,901,675
Balance, shares at Dec. 31, 2019	278,188	84,069,967
Stock-based compensation			2,147,591			2,147,591
Common shares issued upon partial conversion of debt		$ 39,621	681,443			721,064
Common shares issued upon partial conversion of debt, shares		3,962,145
Net loss				(4,657,894)		(4,657,894)
Balance at Mar. 31, 2020	$ 2,782	$ 880,321	31,014,633	(16,785,300)		15,112,436
Balance, shares at Mar. 31, 2020	278,188	88,032,112
Balance at Dec. 31, 2019	$ 2,782	$ 840,700	28,185,599	(12,127,406)		16,901,675
Balance, shares at Dec. 31, 2019	278,188	84,069,967
Net loss						(6,062,360)
Balance at Sep. 30, 2020	$ 2,782	$ 896,020	32,176,064	(18,189,766)	979,541	15,864,641
Balance, shares at Sep. 30, 2020	278,188	89,601,912
Balance at Mar. 31, 2020	$ 2,782	$ 880,321	31,014,633	(16,785,300)		15,112,436
Balance, shares at Mar. 31, 2020	278,188	88,032,112
Common shares issued upon partial conversion of debt		$ 5,699	97,741			103,440
Common shares issued upon partial conversion of debt, shares		569,800
Net loss				582,091		582,091
Balance at Jun. 30, 2020	$ 2,782	$ 886,020	31,112,374	(16,203,209)		15,797,967
Balance, shares at Jun. 30, 2020	278,188	88,601,912
Beneficial conversion feature on convertible debt			632,194			632,194
Warrants issued in connection with private placement			365,431			365,431
Common shares issued upon partial conversion of debt		$ 10,000	66,065			76,065
Common shares issued upon partial conversion of debt, shares		1,000,000
Non-controlling interest in Edgepoint					979,541	979,541
Net loss				(1,986,557)		(1,986,557)
Balance at Sep. 30, 2020	$ 2,782	$ 896,020	$ 32,176,064	$ (18,189,766)	$ 979,541	$ 15,864,641
Balance, shares at Sep. 30, 2020	278,188	89,601,912

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (1,986,557)	$ (4,657,894)	$ (991,126)	$ (976,063)	$ (6,062,360)	$ (3,156,299)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount and deferred finance costs					1,591,261	88,479
Amortization of intangible assets	12,841		12,841		245,104	38,524
Stock-based compensation					2,147,591	340,674
Depreciation on development equipment					27,987
Issuance of common stock in lieu of cash for services						418,136
Change in fair value of derivative	(49,992)				(60,504)		$ (870,268)
Loss on debt conversion	88,817				254,884
Changes in operating assets and liabilities:
Prepaid expenses and other current assets					104,071	35,175
Accounts payable and accrued expenses					644,329	329,760
Accounts payable to related party					(216,680)	569,256
Net cash used in operating activities					(1,324,317)	(1,336,295)
Cash flows from investing activities:
Cash acquired in mergers						182,883
Net cash provided by investing activities						182,883
Cash flows from financing activities:
Proceeds from sales of common stock, net of costs						83,120
Proceeds from Payroll Protection Plan					250,000
Proceeds from short term loan, related party					70,000	148,000
Proceeds from private placement					2,304,541
Net cash provided by financing activities					2,624,541	1,167,120
Net increase in cash and restricted cash					1,300,224	13,708
Cash - beginning of period		$ 81,964		$ 2,498	81,964	2,498	2,498
Cash and restricted cash - end of period	$ 1,382,188		$ 16,206		1,382,188	16,206	$ 81,964
Non cash investing and financing activities:
Common shares issued upon partial conversion of debt					900,569
Recapitalization under reverse merger						3,727,752
Beneficial Conversion Feature on convertible debt and restricted common shares						684,140
Common stock issued for settlement of accounts payable						$ 238,090

Description of Business and Bas

Description of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Presentation	NOTE 1 – DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Description of Business Mateon Therapeutics, Inc. (f/k/a OXiGENE, Inc.) ( “ Mateon Oncotelic PointR Edgepoint” Company In April 2019, Mateon entered into an Agreement and Plan of Merger with Oncotelic (the “ Merger Agreement Merger Sub Merger The Company is a cancer immunotherapy company dedicated to the development of first in class self-immunization protocol (SIP™) candidates for difficult to treat cancers. The Company’s proprietary SIP™ candidates offer advantages over other immunotherapies because they do not require extraction of the tumor or isolation of the antigens, and they have the potential for broad-spectrum applicability for multiple cancer types. The Company’s proprietary product candidates have shown promising clinical activity in phase 2 trials for the treatment of gliomas and pancreatic cancers. The Company aims to translate its unique insights, which span more than three decades of original work using RNA therapeutics, into the deployment of antisense as a RNA therapeutic for diseases which are caused by TGF-beta overexpression, starting with cancer and expanding to Duchenne Muscular Dystrophy (DMD) and others. Oncotelic’s lead product candidate, OT-101, is being developed as a broad-spectrum anti-cancer drug that can also be used in combination with other standard cancer therapies to establish an effective multi-modality treatment strategy for difficult-to-treat cancers. Together, the Company plans to initiate phase 3 clinical trials for OT-101 in both high-grade glioma and pancreatic cancer, and any other indications that may evolve. The Company is developing OT-101 for the various epidemics and pandemics, similar to the current corona virus (“ COVID-19 GMP GMP Note”) In addition, the Company was paid $0.5 million for the completion of a successful in-vivo study of OT-101 in combination with Interluken 2 from Autotelic BIO Co., LTD. (“ ATB In August 2019, Mateon entered into an Agreement and Plan of Merger (the “ PointR Merger Agreement PointR Merger AI Amendment In February 2020, Mateon formed a subsidiary, Edgepoint. Edgepoint is a start-up company that plans to develop technologies and IP related to various unmet issues within the pharma and medical device industries. In addition, the Company is developing artemisinin. Artemisinin, purified from a plant Artemisia annua TM Recent Developments GMP Note In June 2020, Mateon secured $2 million in debt financing, evidenced by a one year convertible note (the “GMP Note”) from GMP, to conduct a clinical trial evaluating OT-101 against COVID-19 bearing 2% annual interest, and is personally guaranteed by Dr. Vuong Trieu, the Chief Executive Officer of Mateon. The GMP Note is convertible into Mateon’s Common Stock upon the GMP Note’s maturity one year from the date of the GMP Note, at Mateon’s Common Stock price on the date of conversion with no discount. GMP does not have the option to convert prior to the GMP Note’s maturity at the end of one year. Such financing will be utilized solely to fund the clinical trial. The Company’s liability under GMP Note commenced to accrue when GMP first began to pay for services related to the clinical trial to our third-party clinical research organization, up to a maximum of $2 million. In October 2020, the GMP paid approximately $0.5 million to the clinical trial organization, which accrued as a liability to the Company under the terms of the GMP Note. JH Darbie & Co., Inc. Private Placement During the three months ended September 30, 2020, the Company raised net proceeds of approximately $2.3 million, between July and September 2020, through JH Darbie & Co., Inc. (“ JH Darbie Units Edgepoint Common Stock Unit Warrants Edgepoint Warrant Mateon Warrant JH Darbie Financing The Company incurred $0.4 million of costs associated with the JH Darbie Financing, of which $0.3 million was paid as direct placement fees to JH Darbie, pursuant to that certain Placement Agent Agreement, dated February 25, 2020 (the “ Darbie Placement Agreement Consent Solicitation On June 25, 2020, the Company commenced a solicitation of shareholder consents (the “ Consent Solicitation Consent Solicitation Statement Stockholders (1) changing the name of the Company to “Oncotelic, Inc.” and to changing the Company’s ticker symbol (the “ Name Change (2) amending the Company’s Amended and Restated 2015 Equity Incentive Plan (the “ 2015 Plan Plan Amendment (3) increasing the authorized number of shares of Common Stock from 150,000,000 to 750,000,000 (the “ Capital Increase (4) amending and restating the certificate of incorporation for the Company (the “ Amended and Restated Certificate The Stockholders approved the Name Change, the Plan Amendment, the Capital Increase, and the Amended and Restated Certificate. On November 5, 2020, the Company filed an amendment to its Certificate of Incorporation with the Secretary of State for the State of Delaware changing its name from “Mateon Therapeutics, Inc.” to “Oncotelic Therapeutics, Inc.” A notice of corporate action has been filed with the Financial Industry Regulatory Authority (FINRA), requesting approval to change its name and ticker symbol. The Company is still awaiting FINRA’s approval on its notice of corporate action, and upon receipt of acceptance, the Company’s ticker symbol will be changed to reflect the Company’s name change. Entry into MOU and Agreement with Windlas On August 19, 2020 the Company executed a memorandum of understanding (the “ MOU “Windlas On September 1, 2020 the Company executed the final MOU with Windlas regarding the development and commercialization of Artemisinin as therapeutic pharmaceutical, nutraceutical and herbal supplement against COVID-19. The ARTI-19 trial has been cleared by India regulatory authorities for initiation. The trial is now registered under CTRI and three sites have been selected, their IRB approval obtained, their staffs have been trained into the protocol/EDC. Additional sites will be added as the trial progressed. Enrollment of patients has already commenced for the trial. The Company and Windlas entered into a License, Development and Commercialization Agreement, dated November 10, 2020 (the “ Commercialization Agreement Please review Note 12 – Subsequent events for more information on updates since September 30, 2020. Principles of Consolidation The consolidated financial statements include the accounts of Mateon and its wholly owned subsidiaries, Oncotelic and PointR; and Edgepoint for which there are non-controlling interests. Intercompany accounts and transactions have been eliminated in consolidation. Basis of Presentation The accompanying consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission including Form 10-Q and Regulation S-X. The information furnished herein reflects all adjustments (consisting of normal recurring accruals and adjustments) which are, in the opinion of management, necessary to fairly state the operating results for the respective periods. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“ US GAAP Liquidity and Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred net losses of approximately $18.2 million since inception of Oncotelic as Mateon’s historical financial statements before the Merger have been replaced with the historical financial statements of Oncotelic prior to the Merger in the financial statements and filings. The Company also has a negative working capital of $7.3 million at September 30, 2020, of which approximately $1.3 million is attributable to assumed negative working capital of Mateon and $2.6 million contingent liability of issuance of common shares of Mateon to PointR shareholders upon achievement of certain milestones in accordance with the PointR Merger Agreement. The Company continues to have negative cash flows from operations through the nine months ended September 30, 2020. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the date of this filing. Management expects to incur additional losses in the foreseeable future and recognizes the need to raise capital to remain viable. The accompanying consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. The Company’s long-term plans include continued development of its current pipeline of products to generate sufficient revenues to cover its anticipated expenses, through either technology transfer or product sales, as well as develop AI technologies either directly or through its subsidiaries. Until the Company is able to generate sufficient revenues from its current pipeline, the Company plans on funding its operations through the sale of equity and/or the issuance of debt, combined with or without warrants or other equity instruments. Between April 2019 and December 2019, the Company entered into various securities purchase agreements (each individually, a “ SPA SPA Note Notes In July 2019, the Company entered into a convertible note purchase agreement with PointR. Such convertible note was converted into shares of Mateon upon the completion of the PointR Merger. During the three months ended September 30, 2020, the Company raised gross proceeds of $2.65 million, between July and September 2020, through JH Darbie & Co., Inc. (“ JH Darbie During the nine months ended September 30, 2020, the Company recorded a total of approximately $1.7 million in service revenues from GMP and ATB. There are no assurances that the Company would be able to generate revenues for services and/or outlicensing fees in the near future. During the nine months ended September 30, 2020, the Company’s CEO provided short term funding of $70,000 to the Company. Although no assurances can be given as to the Company’s ability to deliver on its revenue plans, or that unforeseen expenses may arise, management believes that the potential equity and debt financing or other potential financing will provide the necessary funding for the Company to continue as a going concern. Also, management cannot guarantee any potential debt or equity financing will be available on favorable terms or at all. As such, management does not believe the Company has sufficient cash for 12 months from the date of this report. If adequate funds are not available on acceptable terms, or at all, the Company will need to curtail operations, or cease operations completely.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity-based transactions and disclosure of contingent liabilities at the date of the financial statements and revenues and expense during the reporting period. Actual results could materially differ from those estimates. The Company believes the following critical accounting policies affect its more significant judgments and estimates used in the preparation of the financial statements. Significant estimates include the valuation of goodwill and intangible assets for impairment, deferred tax asset and valuation allowance, and fair value of financial instruments. Cash As of September 30, 2020, and December 31, 2019, the Company held all its cash in banks in the United States of America. The Company considers investments in highly liquid instruments with a maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents as of September 30, 2020 and December 31, 2019. Restricted cash consists of certificates of deposits held at banks as collateral for various purposes. Investment in Equity Securities Prior to the Merger, Oncotelic received Series E Preferred Shares of Adhera Therapeutics, Inc. (“ Adhera ASC ASC 321 Debt issuance Costs and Debt discount Issuance costs are specific incremental costs that are (1) paid to third parties and (2) directly attributable to the issuance of a debt or equity instrument. The issuance costs attributable to the initial sale of the instrument should be offset against the associated proceeds in the determination of the instrument’s initial net carrying amount. Debt issuance costs and debt discounts are being amortized over the lives of the related financings on a basis that approximates the effective interest method. Costs and discounts are presented as a reduction of the related debt in the accompanying condensed balance sheets if related to the issuance of debt or presented as a reduction of Additional Paid in capital if related to the issuance of an equity instrument. The Company applied the relative fair value to allocate the issuance costs among freestanding instruments that form part of the same transaction. Fair Value of Financial Instruments The carrying value of cash, accounts payable and accrued expense approximate their fair values based on the short-term maturity of these instruments. As defined in ASC 820, “Fair Value Measurements and Disclosures,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent measurement. The three levels of the fair value hierarchy defined by ASC 820 are as follows: ● Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities. ● Level 2 – Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars. ● Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value. Other than the restricted cash of $20,000, the Company did not have any Level 1 or Level 2 assets and liabilities at September 30, 2020. Carrying Fair Value Measurement Using At September 30, 2020 Value Level 1 Level 2 Level 3 Total Restricted Cash – CDs at Bank $ 20,000 $ 20,000 $ - $ - $ 20,000 $ 20,000 $ - $ - $ - $ 20,000 The derivative liabilities associated with its 2019 convertible note debt /financing (see Note 5), consisted of conversion feature derivatives at September 30, 2020 hence are classified as Level 3 fair value measurements. The table below sets forth a summary of the changes in the fair value of the Company’s derivative liabilities classified as Level 3 as of September 30, 2020: Conversion Feature Balance at December 31, 2019 $ 540,517 New derivative liability 870,268 Reclassification to additional paid in capital from conversion of debt to common stock (573,811 ) Change in fair value (60,504 ) Balance at September 30, 2020 $ 776,470 As of September 30, 2020, and December 31, 2019, the Company estimated the fair value of the conversion feature derivatives embedded in the convertible debentures based on assumptions used in the Black-Scholes valuation model. The key valuation assumptions used consists, in part, of the price of the Company’s Common Stock, a risk free interest rate based on the yield of a Treasury note and expected volatility of the Company’s Common Stock all as of the measurement dates. The Company used the following assumptions to estimate fair value of the derivatives as of September 30, 2020: September 30, 2020 Risk free interest 0.13 % Market price of share $ 0.18 Life of instrument in years 1.56 – 1.85 Volatility 150.77 % Dividend yield 0 % When the Company changes its valuation inputs for measuring financial liabilities at fair value, either due to changes in current market conditions or other factors, it may need to transfer those liabilities to another level in the hierarchy based on the new inputs used. The Company recognizes these transfers at the end of the reporting period that the transfers occur. For the period ended September 30, 2020, there were no transfers of financial assets or financial liabilities between the hierarchy levels. Other Fair Value Measurements As of the closing of the Company’s first three rounds of offering under a private placement memorandum with JH Darbie, the estimated grant date fair value of approximately $0.2 per share associated with the warrants to purchase up to 2,915,000 shares of common stock issued in this offering, or a total of approximately $0.4 million, was recorded to additional paid-in capital on a relative fair value basis. All warrants sold in this offering had an exercise price of $0.20 per share of the Company stock or $1.00 per share of Edge Point, subject to adjustment, are exercisable immediately and expire three years from the date of issuance. The fair value of the warrants was estimated using a Black Scholes valuation model using the following input values Expected Term 1.5 years Expected volatility 184.7%-191.9 % Risk-free interest rates 0.13%-0.15 % Dividend yields 0.00 % Net Income (Loss) Per Share Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share includes the effect of Common Stock equivalents (notes convertible into Common Stock, stock options and warrants) when, under either the treasury or if-converted method, such inclusion in the computation would be dilutive. The following number of shares have been excluded from diluted loss since such inclusion would be anti-dilutive: Three and Nine Months Ended September 30, 2020 2019 Convertible notes 20,237,084 10,000,000 Stock options 6,130,004 6,145,044 Warrants 18,152,500 19,515,787 Potentially dilutive securities 44,519,588 35,660,831 Stock-Based Compensation The Company applies the provisions of ASC 718, Compensation—Stock Compensation (“ ASC 718 For stock options issued to employees and members of the Board of Directors (the “ Board Pursuant to ASU 2018-07 Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, the Company accounts for stock options issued to non-employees for their services in accordance with ASC 718. The Company uses valuation methods and assumptions to value the stock options that are in line with the process for valuing employee stock options noted above. For warrants issued in connection with fund raising activities, the Company estimates the grant date fair value of each warrant using the Black-Scholes pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the warrant, the expected volatility of the Common Stock consistent with the expected life of the warrant, risk-free interest rates and expected dividend yields of the Common Stock. If the warrants are issued upon termination or cancellation of prior issued warrants, then the Company estimates the grant date fair value of the new warrants using the Black-Scholes pricing model and evaluates whether the new warrants are deemed as equity instruments or liability instruments. If the warrants are deemed to be equity instruments, the Company records stock compensation expense and an addition to additional paid in capital. If however, the warrants are deemed to be liability instruments, then the fair value is treated as a deemed dividend and credited to additional paid in capital. Impairment of Long-Lived Assets The Company reviews long-lived assets, including definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows or appraised values, depending on the nature of the assets. For the nine months ended September 30, 2020 and year ended December 31, 2019, there were no impairment losses recognized for long-lived assets. Intangible Assets The Company records its intangible assets at cost in accordance with ASC 350, Intangibles – Goodwill and Other. The Company reviews the intangible assets for impairment on an annual basis or if events or changes in circumstances indicate it is more likely than not that they are impaired. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. If the review indicates the impairment, an impairment loss would be recorded for the difference of the value recorded and the new value. For the nine months ended September 30, 2020 and 2019, there were no impairment losses recognized for intangible assets. Goodwill Goodwill represents the excess of the purchase price of acquired business over the estimated fair value of the identifiable net assets acquired. Goodwill is not amortized but is tested for impairment at least once annually, at the reporting unit level or more frequently if events or changes in circumstances indicate that the asset might be impaired. The goodwill impairment test is applied by performing a qualitative assessment before calculating the fair value of the reporting unit. If, on the basis of qualitative factors, it is considered not more likely than not that the fair value of the reporting unit is less than the carrying amount, further testing of goodwill for impairment would not be required. Otherwise, goodwill impairment is tested using a two-step approach. The first step involves comparing the fair value of the reporting unit to its carrying amount. If the fair value of the reporting unit is determined to be greater than its carrying amount, there is no impairment. If the reporting unit’s carrying amount is determined to be greater than the fair value, the second step must be completed to measure the amount of impairment, if any. The second step involves calculating the implied fair value of goodwill by deducting the fair value of all tangible and intangible assets, excluding goodwill, of the reporting unit from the fair value of the reporting unit as determined in step one. The implied fair value of the goodwill in this step is compared to the carrying value of goodwill. If the implied fair value of the goodwill is less than the carrying value of the goodwill, an impairment loss equivalent to the difference is recorded. For the nine months ended September 30, 2020 and 2019, there were no impairment losses recognized for Goodwill. Convertible Instruments The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with ASC 815 “Derivatives and Hedging”. ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur, and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Professional standards also provide an exception to this rule when the host instrument is deemed to be conventional as defined under professional standards as “The Meaning of Conventional Convertible Debt Instrument.” The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with ASC 470-20 “Debt – Debt with Conversion and Other Options.” Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying Common Stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Original issue discounts (“ OID ASC 815-40 “Derivatives and Hedging – Contracts in Entity’s Own Equity” provides that, among other things, generally, if an event occurs that is not within the entity’s control could or would require net cash settlement, then the contract shall be classified as an asset or a liability. Revenue Recognition The Company recognizes revenue in accordance with ASU Under ASU 2014-9, the Company recognizes revenue when its customers obtain control of the promised good or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. The Company applies the following five-step process: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of ASU 2014-09, the Company identifies the performance obligation(s) in the contract by assessing whether the goods or services promised within each contract are distinct. The Company then recognizes revenue for the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The Company anticipates generating revenues from rendering services to other third party customers for the development of certain drug products and/or in connection with certain out-licensing agreements. In the case of services rendered for development of the drugs, revenue is recognized upon the achievement of the performance obligations or over time on a straight-line basis over the extended service period. In the case of out-licensing contracts, the Company records revenues either (i) upon achievement of certain pre-defined milestones when there is no obligation of the Company achieve any performance obligations in connection with the said pre-defined milestones, or (ii) upon achievement of the performance obligations if the milestones require the Company to provide the performance obligations. The Company occasionally collects advance payments from customers toward commitments to provide services or performance obligations, in which case the advance payment is recorded as a liability until the obligations are fulfilled and revenue is recognized. Research Service Agreement between GMP and Mateon Therapeutics Inc./Oncotelic Inc. (“Mateon Entities”). In February 2020, Oncotelic and GMP entered into a research and services agreement (the “ Agreement Product Supplement Agreement with Autotelic BIO Oncotelic had entered into a license agreement in February 2018 (the “ ATB Agreement Combined Product Research & Development Costs In accordance with ASC 730-10-25 “Research and Development”, research and development costs are charged to expense as and when incurred. Recent Accounting Pronouncements In January 2017, the Financial Accounting Standards Board (“ FASB ASU In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which defers the effective date of ASU 2014-09 for all entities by one year. ASU 2014-09 became effective on January 1, 2018. The ASU also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. The Company adopted ASU 2015-14 during the nine months ended September 30, 2020 as till then, no revenue was earned by the Company. In August 2020, the FASB issued “ASU 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)” which simplifies the accounting for convertible instruments. The guidance removes certain accounting models which separate the embedded conversion features from the host contract for convertible instruments. Either a modified retrospective method of transition or a fully retrospective method of transition is permissible for the adoption of this standard. Update No. 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted no earlier than the fiscal year beginning after December 15, 2020. The Company is currently evaluating the potential impact of the Update on its financial statements All other newly issued but not yet effective accounting pronouncements have been deemed to be not applicable or immaterial to the Company.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	NOTE 3 – GOODWILL AND INTANGIBLE ASSETS Mateon completed the Merger with Oncotelic, which gave rise to Goodwill of $4,879,999. Further, Mateon added goodwill of $16,182,456 upon the completion of the Merger with PointR. In general, the goodwill is tested on an annual impairment date of December 31. However, since both mergers were completed in 2019 and both assets are currently being developed for various cancer and COVID-19 therapies, the Company does not believe the there are any factors or indications that the goodwill is impaired. Assignment and Assumption Agreement with Autotelic, Inc. In April 2018, Oncotelic entered into an Assignment and Assumption Agreement (the “ Assignment Agreement IP Intangible Asset Summary The following table summarizes the balances as of September 30, 2020 and December 31, 2019, of the intangible assets acquired, their useful life, and annual amortization: September 30, 2020 Remaining Estimated Useful Life (Years) Intangible asset – Intellectual Property $ 819,191 18.26 Intangible asset – Capitalization of license cost 190,989 18.26 1,010,180 Less Accumulated Amortization (124,133 ) Total $ 886,047 December 31, 2019 Remaining Estimated Useful Life (Years) Intangible asset – Intellectual Property $ 819,191 18.68 Intangible asset – Capitalization of license cost 190,989 18.68 1,010,180 Less Accumulated Amortization (85,608 ) Total $ 924,572 Amortization of identifiable intangible assets for the three months ended September 30, 2020 and 2019 was $12,841 and $12,841, respectively. Amortization of identifiable intangible assets for the nine months ended September 30, 2020 and 2019 was $38,524 and $38,524, respectively. The future yearly amortization expense over the next five years and thereafter are as follows: For the years ended December 31, Remainder of 2020 $ 12,841 2021 51,365 2022 51,365 2023 51,365 2024 51,365 Thereafter 667,746 $ 886,047 In-Process Research & Development (IPR&D) Summary The following table summarizes the balances as of September 30, 2020 of the IPR&D assets acquired during the three months ended December 31, 2019. The Company will evaluate, on an annual basis, for any impairment and record an impairment if identified. No similar balances were present in 2019: September 30, 2020 Remaining Estimated Useful Life (Years) Intangible asset – Intellectual Property $ 1,377,200 4.25 1,377,200 Less Accumulated Amortization (206,580 ) Total $ 1,170,620 Amortization of identifiable intangible assets for the three months ended September 30, 2020 and 2019 was $68,860 and $0, respectively. Amortization of identifiable intangible assets for the nine months ended September 30, 2020 and 2019 was $206,580 and $0, respectively. The future yearly amortization expense over the next five years and thereafter are as follows: For the years ended December 31, Remainder of 2020 $ 68,860 2021 275,440 2022 275,440 2023 275,440 2024 275,440 $ 1,170,620

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	9 Months Ended
	Sep. 30, 2020
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	NOTE 4 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expense consists of the following amounts: September 30, 2020 December 31, 2019 Accounts payable $ 2,024,261 $ 1,793,033 Accrued expense 707,359 261,950 $ 2,731,620 $ 2,054,983 September 30, 2020 December 31, 2019 Accounts payable – related party $ 385,002 $ 601,682

Convertible Debentures. Notes a

Convertible Debentures. Notes and Other Debt	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Convertible Debentures. Notes and Other Debt	NOTE 5 – CONVERTIBLE DEBENTURES. NOTES AND OTHER DEBT As of September 30, 2020, SPAs with convertible debentures and notes, net of debt discount, consist of the following amounts: September 30, 2020 Convertible debentures 10% Convertible note payable, due June 12, 2022 – Peak One $ 11,183 10% Convertible note payable, due April 23, 2022 - TFK 33,823 10% Convertible note payable, due April 23, 2022 – Related Party 10,197 10% Convertible note payable, due April 23, 2022 – Bridge Investor 51,817 10% Convertible note payable, due August 6, 2022 – Bridge Investor 163,485 270,505 Fall 2019 Notes 5% Convertible note payable – Stephen Boesch 250,648 5% Convertible note payable – Related Party 250,477 5% Convertible note payable – Dr. Sanjay Jha (Through his family trust) 249,997 5% Convertible note payable – CEO, CTO & CFO 84,268 5% Convertible note payable – Bridge Investors 172,647 1,008,037 Other Debt Short term debt from CEO 70,000 Total of debentures, notes and other debt $ 1,348,542 As of December 31, 2019, convertible debentures and notes, net of debt discount, consist of the following amounts: December 31, 2019 10% Convertible note payable, due April 23, 2022 – Peak One $ 115,623 10% Convertible note payable, due June 12, 2022 – Peak One (81,735 ) 10% Convertible note payable, due April 23, 2022 - TFK 115,623 10% Convertible note payable, due April 23, 2022 – Related Party (12,663 ) 10% Convertible note payable, due April 23, 2022 – Bridge Investor (2,748 ) 10% Convertible note payable, due August 6, 2022 – Bridge Investor 26,824 160,924 Fall 2019 Notes 5% Convertible note payable – Stephen Boesch 187,785 5% Convertible note payable – Vuong Trieu* 187,785 5% Convertible note payable – Sanjay Jha (Through his family trust) 187,785 5% Convertible note payable – CEO, CTO & CFO 77,620 5% Convertible note payable – Bridge Investors 159,025 800,000 Total of notes and other debt $ 960,924 The gross principal balances on the convertible debentures listed above totaled $1,000,000 and originally included an initial debt discounts totaling $800,140, resulting from the recording of the original issue discount, the related financing costs, the beneficial conversion feature for the intrinsic value of the non-bifurcated conversion option and the restricted shares issued contemporaneously with the convertible notes. Total amortization expense related to these debt discounts related to the convertible debentures was $611,681 and $88,479 for the nine months ended September 30, 2020 and 2019, respectively. In addition, during the nine months ended September 30, 2020, we recorded additional and accelerated amortization of debt discounts, which was created from the bifurcation of the conversion option related the host hybrid instruments, of $262,556 upon the partial conversion of debt by Peak One and TFK to shares of the Company’s common stock. The total unamortized debt discount at September 30, 2020, was approximately $321,290. All the above notes issued to Peak One, TFK, our CEO and the bridge investors reached the 180 days prior to the end of the three months ended March 31, 2020. As such, all the note holders had the ability to convert that debt into equity at the variable conversion price of 65% of the Company’s lowest traded price after the first 180 days or at the lower of the Fixed Price or 55% of the Company’s traded stock price under certain circumstances. This gave rise to a derivative feature within the debt instrument. As of December 31, 2019, we had a derivative liability of approximately $541,000. The Company recorded additional derivative liability of approximately $870,000 during the nine months ended September 30, 2020 since the conversion option attached to certain notes became convertible into a variable number of shares of our common stock. The Company also extinguished approximately $574,000 of derivative liability following the conversion of certain notes to the Company’s common stock in the nine months ended September 30, 2020. Following the recognition as derivative liability of the embedded conversion options, the Company fully amortized the remaining unamortized beneficial conversion feature for approximately $232,000, recorded an initial $258,070 from the initial recognition of the debt discount following the bifurcation of the embedded conversion option. As of September 30, 2020, the Company had a derivative liability of approximately $776,000 and a change in fair value of approximately $60,500. Bridge Financing Peak One Financing On April 17, 2019, the Company entered into a Securities Purchase Agreement (the “ Purchase Agreement Buyer Peak One Convertible Note Shares Purchase and Sale Transaction The Convertible Note has a principal balance of $200,000, including a 10%$ OID of $20,000 and $5,000 in debt issuance costs, receiving net proceeds of $175,000, with a maturity date of April 23, 2022. Upon the occurrence of certain events of default, the Buyer, amongst other remedies, has the right to charge a penalty in a range of 18% to 40% dependent on the specific default event. Amounts due under the Convertible Note may also be converted into shares (the “ Tranche #1 Conversion Shares Fixed Price The issuance of the Convertible Note resulted in a discount from the beneficial conversion feature totaling $84,570, including $52,285 related to the beneficial conversion feature and a discount from the issuance of restricted stock of 350,000 shares for $32,285. Total amortization of these OID and debt issuance cost discounts totaled $84,376 for the nine months ended September 30, 2020. Total unamortized discount on this note was $0 as of September 30, 2020. On June 12, 2019, the Company entered into an amendment of the Purchase Agreement (“ Amendment #1 On June 12, 2019, the Buyer purchased Convertible Note Tranche #2 (“ Tranche #2 The issuance of Tranche #2 resulted in a discount from the beneficial conversion feature totaling $180,000, including $132,091 related to the conversion feature and a discount from the issuance of restricted stock of 350,000 shares for $47,909. Total amortization of these OID and debt issuance cost discounts totaled $36,187 for the nine months ended September 30, 2020. Total unamortized discount on this note was $127,768 as of September 30, 2020. On November 5, 2019, the Company and Peak One amended the Convertible Note under Tranche #1 to extend the date of conversion of the Convertible Note into Common Stock of the Company at 65% of the traded price of the Company’s Common Stock until January 8, 2020. This amendment put a temporary hold on Peak One to convert the debt under Tranche 1. This restriction did not apply if Peak One opted to convert the Convertible Note at $0.10. The Company compensated Peak One 300,000 shares of the Company’s Common Stock for delaying the conversion until January 18, 2020. Such shares were issued to Peak One on November 14, 2019. Non-cash compensation expense of $60,000 was recorded for such issuance. Peak One converted $200,000 of Tranche 1 out of their total debt into 2,581,945 shares of Mateon during the nine months ended September 30, 2020. Further, Peak One converted $100,000 of Tranche 2 of their total debt into 1,000,000 shares of Mateon during the nine months ended September 30, 2020. As such, the total outstanding debt for Peak One was $100,000 as of September 30, 2020. TFK Financing On April 23, 2019, the Company, entered into a Convertible Note (the “ TFK Note TFK TFK Conversion Shares The issuance of the TFK Note resulted in a discount from the beneficial conversion feature totaling $84,570, including $52,285 related to the beneficial conversion feature and a discount from the issuance of restricted stock of 350,000 shares for $32,285. Total amortization of these OID and debt issuance cost discounts totaled $80,788 for the nine months ended September 30, 2020. Total unamortized discount on this note was $3,589 as of September 30, 2020. On November 5, 2019, the Company and TFK amended the TFK Convertible Note to extend the date of conversion of the Convertible Note into Common Stock of the Company at 65% of the traded price of the Company’s Common Stock until January 8, 2020. This restriction did not apply if TFK wished to convert the Convertible Note at $0.10 per share. The Company compensated TFK 300,000 shares of the Company’s Common Stock for delaying the conversion until January 8, 2020. Such shares were issued to TFK on November 14, 2019. Non-cash compensation expense of $60,000 was recorded for such issuance. TFK converted $133,430 of their total debt into 1,950,000 shares of Mateon during the nine months ended September 30, 2020. As such, the total outstanding debt for TFK was $66,570 as of September 30, 2020. Notes with Officer and Bridge Investor On April 17, 2019, the Company entered into a Securities Purchase Agreement (the “ Bridge SPA On April 23, 2019, the Company entered into a convertible note with our Chief Executive Officer, Vuong Trieu, Ph. D. (the “ Trieu Note Trieu Conversion Shares Fixed Price th The issuance of the Trieu Note resulted in a discount from the beneficial conversion feature totaling $131,555 related to the conversion feature. Total amortization of the 10% OID discount and beneficial conversion feature totaled $4,095 for the nine months ended September 30, 2020. Total unamortized discount on this note was $8,568 as of September 30, 2020. On April 23, 2019, pursuant to the Bridge SPA the Company entered into Convertible Note Tranche #1 (“ Tranche #1 Bridge SPA Conversion Shares Fixed Price The issuance of the note resulted in a discount from the beneficial conversion feature totaling $28,445. Total amortization of the OID and discount totaled $888 for the nine months ended September 30, 2019. Total unamortized discount on this note was $1,849 as of September 30, 2020. On August 6, 2019, pursuant to the Bridge SPA the Company entered into Convertible Note Tranche #2 (“ Tranche #2 th The issuance of the note resulted in a discount from the beneficial conversion feature totaling $175,000. Total amortization of the OID and discount totaled $157,779 for the nine months ended September 30, 2020. Total unamortized discount on this note was $15,396 as of September 30, 2020. All the above notes issued to Peak One, TFK, our CEO and the bridge investors reached the 180 days prior to the end of the nine months ended September 30, 2020. As such, all the note holders had the ability to convert that debt into equity at the variable conversion price of 65% % of the Company’s lowest traded price after the first 180 days or at the lower of the Fixed Price or 55% of the Company’s traded stock price under certain circumstances. This gave rise to a derivative feature within the debt instrument. As of December 31, 2019, we had a derivative liability of approximately $541,000. Following the initial bifurcation of the conversion features related to certain hybrid convertible notes instruments, the Company recorded an initial fair value of such derivative of $870,268. Following conversion of certain notes to the Company’s common stock, the Company reversed such derivative liability by approximately $573,800. This resulted in a change in fair value of $60,504. As of September 30, 2020, the derivative liability had a fair value of approximately $776,000. During the nine months ended September 30, 2020, the Company fully amortized for $232,054 the remaining unamortized beneficial conversion feature since the conversion feature of certain hybrid instruments were separated and accounted for as derivative liability. The Company recorded an initial debt discount of $258,070 resulting from the bifurcation of the conversion feature representing the net carrying amount of the underlying notes since the fair value of the initial derivative liability exceeds the net carrying amount of the underlying notes. Convertible Note with PointR Data, Inc. In July 2019, the Company entered into a Note Purchase Agreement with PointR (the “PointR Note Purchase Agreement”). Pursuant to the PointR Note Purchase Agreement, Mateon issued a Convertible Promissory Note to PointR in the principal amount of $200,000 (the “ PointR Convertible Note Qualified Financing In November 2019, the PointR Convertible Note, with accrued interest of $4,603 thereon, was converted into Company’s Series A Preferred Stock and is a part of the total consideration of 84,475 shares of Mateon’s Series A Preferred Stock issued to the PointR shareholders upon the completion of the PointR Merger. Since the conversion occurred prior to the Qualified Financing, the Company did not have to evaluate the conversion feature under ASC 470-20 and ASC 815. Fall 2019 Debt Financing In December 2019, Mateon closed its Fall 2019 Debt Financing, raising an additional $500,000 bringing the gross proceeds of all debt financings under the Fall 2019 Debt Financing to $1,000,000. The Company entered into those certain Note Purchase Agreements (the “ Fall 2019 Note Purchase Agreements Fall 2019 Notes All the Fall 2019 Notes provide for interest at the rate of 5% per annum and are unsecured. All amounts outstanding under the Fall 2019 Notes become due and payable upon the approval of the holders of a majority of the principal amount of outstanding Fall 2019 Notes (the “ Majority Holders Maturity Date The Majority Holders have the right, at any time not more than five (5) days following the Maturity Date, to elect to convert all, and not less than all, of the outstanding accrued and unpaid interest and principal on the Fall 2019 Notes. The Fall 2019 Notes may be converted, at the election of the Majority Holders, either (a) into shares of the Company’s Common Stock at a conversion price of $0.18 per share, or (b) into shares of common stock of the Edgepoint, at a conversion price of $5.00 (based on a $5.0 million pre-money valuation) of Edgepoint and 1,000,000 shares outstanding. The issuance of the Fall 2019 Notes resulted in a discount from the beneficial conversion feature totaling $222,222 related to the conversion feature. Total amortization of the discount totaled $111,112 and $0 for the nine months ended September 30, 2020 and 2019, respectively; and $55,556 and $0 for the three months ended September 30, 2020 and 2019, respectively. As of September 30, 2020, the total unamortized discount on these notes was $88,888. Further, the Company recorded interest expense of $12,500 and $37,500 for the three and nine months ended September 30, 2020, on these Fall 2019 Notes. The total amount outstanding under the Fall 2019 Notes, including accrued interest thereon and net of discounts, as of September 30, 2020 and December 31, 2019 was $1,008,037 and $1,003,870, respectively. Paycheck Protection Program In April 2020, the Company, entered into a Paycheck Protection Program Promissory Note (the “ PPP Note PPP Loan Lender PPP CARES Act SBA The PPP Loan matures on April 21, 2022 and bears interest at a rate of 1.00% per annum. The PPP Loan is payable in 17 equal monthly payments commencing November 21, 2020. The PPP Loan may be prepaid at any time prior to maturity with no prepayment penalties. All or a portion of the PPP Loan may be forgiven by the SBA and the Lender upon application by the Company not later than December 31, 2020 upon documentation of expenditures in accordance with the SBA requirements. Other short-term loans During the nine months ended September 30, 2020, the Company’s CEO provided additional funding of $70,000 to the Company.

Private Placement and JH Darbie

Private Placement and JH Darbie Financing	9 Months Ended
	Sep. 30, 2020
Private Placement And Jh Darbie Financing
Private Placement and JH Darbie Financing	NOTE 6 - PRIVATE PLACEMENT AND JH DARBIE FINANCING During the three months ended September 30, 2020, the Company entered into subscription agreements with certain accredited investors pursuant to the JH Darbie Financing, whereby the Company issued and sold a total of 53 Units, for total gross proceeds of approximately $2.65 million or $2.31 million, net of fees paid to JH Darbie pursuant to the Darbie Placement Agreement, with each Unit consisting of: ■ 25,000 shares of Edgepoint Common Stock for a price of $1.00 per share of Edgepoint Common Stock. ■ One convertible promissory note, convertible into up to 25,000 shares of Edgepoint Common Stock, at a conversion price of $1.00 per share or up to 138,889 shares of the Company’s Common Stock, at a conversion price of $0.18 per share. ■ 50,000 warrants to purchase an equivalent number of shares of Edgepoint Common Stock at $1.00 per share or an equivalent number of shares of the Company’s Common Stock at $0.20 per share with a three-year expiration date. As of September 30, 2020, funds received under the JH Darbie Financing, net of debt discount, consist of the following amounts: September 30, 2020 Convertible promissory notes Subscription agreements - accredited investors $ 612,892 Subscription agreements – related party 33,274 Total convertible promissory notes $ 646,166 The Company incurred approximately $0.4 million of issuance costs, including legal costs of approximately $39,000, that are incremental costs directly related to the issuance of the various instruments bundled in the offering. Concurrently with the sale of the Units, JH Darbie is granted, for nominal consideration, a warrant, exercisable over a five-year period, to purchase such number of Units equal 10% of the number of Units sold in the JH Darbie Financing. The Company granted 5.3 Units to JH Darbie pursuant to the Darbie Placement Agreement. The terms of convertible notes are summarized as follows: ■ Term: June 30, 2021. ■ Coupon: 16%. ■ Convertible at the option of the holder at any time in the Company’s Common Stock or Edgepoint Common Stock. ■ The conversion price is initially set at $0.18 per share for the Company’s Common Stock or $1.00 for Edgepoint Common Stock, subject to adjustment. The Company allocated the proceeds among the freestanding financial instruments that were issued in the single transaction using the relative fair value method, which affects the determination of each financial instrument initial carrying amount. The Company utilized the relative fair value method as none of the freestanding financial instruments issued as part of the single transaction are measured at fair value. Under the relative fair value method, the Company makes separate estimates of the fair value of each freestanding financial instrument and then allocates the proceeds in proportion to those fair value amounts. The Company recorded non-controlling interests of approximately $1 million in Edgepoint. Non-controlling interests represent the portion of net assets in consolidated entities that are not owned by the Company and are reported as a component of equity in the unaudited condensed consolidated balance sheets. The Company recorded an initial debt discount of approximately $0.6 million representing the intrinsic value of the conversion option embedded in the convertible debt instrument based upon the difference between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. The Company recognized amortization expense related to the debt discount and debt issuance costs of $162,267 for the three and nine months ended September 30, 2020 respectively, and $0 for the three and nine months ended September 30, 2019, respectively, which is included in interest expense in the condensed statements of operations.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2020
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 7 - RELATED PARTY TRANSACTIONS Master Service Agreement with Autotelic Inc. In October 2015, Oncotelic entered into a Master Service Agreement (the “ MSA Expenses related to the MSA were $6,011 and $291,887 for the three and nine months ended September 30, 2020, respectively, as compared to $309,194 and $1,004,315 for the same periods of 2019 In January 2019, Oncotelic issued a total of 80,772 shares of its common stock with a fair value of $4.00 per share to Autotelic, Inc. in lieu of cash for the settlement of outstanding accounts payable. Notes Payable and Short-Term Loan – Related Party In April 2019, Mateon issued a convertible note to Dr. Trieu totaling $164,444, including OID of $16,444, receiving net proceeds of $148,000, which was used by the Company for working capital and general corporate purposes (See Note 5). The Company issued a Fall 2019 Note to Dr. Trieu in the principal amount of $250,000, which also offset certain amounts due Dr. Trieu in the amount of $35,000 due to him and was converted into debt. During the nine months ended September 30, 2020, Dr. Trieu provided additional short-term funding of $70,000 to the Company. During the three months ended September 30, 2020, Dr. Trieu purchased 3 Units under the private placement for a total of $150,000. Artius Consulting Agreement On March 9, 2020, the Company and Artius Bioconsulting, LLC (“ Artius Artius Agreement Artius Agreement Effective Date Under the terms of the Artius Agreement, the Company agreed to grant to Artius, subject to approval by the Mateon’s Board of Directors and pursuant to the Company’s 2017 Equity Incentive Plan, 148,837 restricted shares of Mateon’s Common Stock, in addition to a 30% pre-financing ownership stake in EdgePoint AI. The Artius Agreement contemplates that Mr. King will generally provide his services at a rate of $237 per hour, not to exceed 44 hours per month and payable monthly, and to reimburse Mr. King for reasonable and necessary expenses incurred by him or Artius in connection with providing services to the Company. Either the Company or Artius may terminate the Artius Agreement at any time, for any reason following the Artius Agreement Effective Date. The Artius Agreement will automatically renew one year from the Artius Agreement Effective Date, unless the Parties agree to terminate the Artius Agreement at that time. The Company recorded $106,712 as expense during the nine months ended September 30, 2020 related to this Agreement. No similar expense was recorded in 2019. Maida Consulting Agreement Effective May 5, 2020, the Company and Dr. Anthony Maida, one of our Board and Committee members, entered into an independent consulting agreement, commencing April 1, 2020 (the “ Maida Agreement Pursuant to the terms of the Maida Agreement, the Company will grant to Dr. Maida 400,000 restricted shares or stock options of Mateon’s Common Stock corresponding to $80,000 at the stock value of $0.20 per share, to vest on May 5, 2021. The Company will also pay Dr. Maida $15,000 per month for a minimum of 20 hours per week, in in addition to reimbursement of reasonable and necessary expenses incurred by Dr. Maida in connection with his services to the Company. Either the Company or Dr. Maida may terminate the Maida Agreement, for any reason, upon 30 days advance written notice. Dr. Maida was appointed the Chief Clinical Director for Mateon effective July 7, 2020. As of the date of this Quarterly Report, Dr. Maida continues to provide his services under the consulting agreement. The Company recorded $45,000 and $90,000 as expense under the consulting agreement during the three and nine months ended September 30, 2020. No similar expense was recorded during the same periods in 2019. Reimbursement of expenses to Autotelic Inc. During the nine months ended September 30, 2020, the Company reimbursed to Autotelic Inc. $261,246 for healthcare insurance and 401K services at cost. No similar reimbursements were recorded during the same period in 2019.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Stockholders' Equity	NOTE 8 – STOCKHOLDERS’ EQUITY The following transactions affected the Company’s Stockholders’ Equity: Equity Transactions During the Period Prior to the Merger Issuance of Common Stock In January 2019, Oncotelic issued 11,250 shares of Common Stock with a fair value of $4.00 per share to an employee in lieu of cash for compensation. In January 2019, Oncotelic issued a total of 80,772 shares of Common Stock with a fair value of $4.00 per share to Autotelic, Inc. in lieu of cash for the settlement of outstanding accounts payable and services received. In January 2019, Oncotelic issued a total of 20,750 shares of Common Stock with a fair value of $4.00 per share to two separates investors for $83,000 in cash. In March 2019, Oncotelic issued 80,594 shares of Common Stock with a fair value of $4.00 per share to various employees in lieu of cash for accrued compensation. In April 2019, Oncotelic issued a total of 150,000 shares of Common Stock to two investors as a result of the conversion of warrants for $120 in cash. Equity Transactions During the Period Since the Merger Issuance of Preferred Stock In April 2019, pursuant to the Merger, Mateon issued 193,713 shares of Series A Preferred Stock in exchange for 77,154 shares of Oncotelic Common Stock. In November 2019 Mateon issued 84,475 shares of Series A Preferred Stock to PointR in exchange of 11,135,935 shares of PointR Common Stock upon the consummation of the PointR merger. Issuance of Common Stock during the three and nine months ended September 30, 2020 In February 2020, Mateon issued 500,000 shares of its Common Stock to Peak One in connection with the part conversion of one of their convertible notes payable. (See Note 5). In February 2020, Mateon issued 1,200,000 shares of its Common Stock to Peak One in connection with the part conversion of one of their convertible notes payable. (See Note 5) In March 2020, Mateon issued 750,000 shares of its Common Stock to TFK in connection with the part conversion of the TFK Note. (See Note 5). In March 2020, Mateon issued 500,000 shares of its Common Stock to Peak One in connection with the part conversion of one of their convertible notes payable. (See Note 5) In March 2020, Mateon issued 1,012,145 shares of its Common Stock to TFK in connection with the part conversion of the TFK Note. (See Note 5). In June 2020, Mateon issued 569,800 shares of its Common Stock to Peak One in connection with the full conversion of one of their convertible notes payable. (See Note 5) In July 2020, Mateon issued 1,000,000 shares of its Common Stock to Peak One in connection with the partial conversion of Tranche 2 of their convertible notes payable. (See Note 5) Issuance of Common Stock in 2019 In April, 2019, pursuant to the Merger, Mateon issued 41,000,033 shares of Common Stock in exchange for 10,318,746 shares of Oncotelic common stock. (See Note 3) In April 2019, Mateon issued 700,000 restricted shares of its Common Stock with a fair value of $0.11 per share to two noteholders in connection with convertible notes payable. (See Note 5) In June 2019, Mateon issued 350,000 restricted shares of its Common Stock with a fair value of $0.18 per share in connection with a convertible note payable. (See Note 5) In June 2019, Mateon issued 300,000 restricted shares of its Common Stock to Peak One with a fair value of $0.20 to extend the date of conversion of the Peak One Tranche #1 Note into Common Stock of Mateon at 65% of the traded price of Mateon’s Common Stock until January 18, 2020. This restriction did not apply if Peak One wished to convert the Peak One Tranche #1 Note at $0.10. The Company recorded a cost of $60,000 in lieu of such issuance. In November 2019, Mateon issued 300,000 restricted shares of its Common Stock to TFK with a fair value of $0.20 to extend the date of conversion of the TFK Note into Common Stock of Mateon at 65% of the traded price of Mateon’s Common Stock until January 8, 2020. This restriction did not apply if TFK wished to convert the TFK Note at $0.10 per share. The Company recorded a cost of $60,000 in lieu of such issuance.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2020
Compensation Related Costs [Abstract]
Stock-Based Compensation	NOTE 9 – STOCK-BASED COMPENSATION Options Pursuant to the Merger, Mateon’s Common Stock and corresponding outstanding options survived. The below information details Mateon’s associated option activity pre and post merger. As of September 30, 2020, options to purchase Mateon’s Common Stock were outstanding under three stock option plans – the 2017 Equity Incentive Plan (the “ 2017 Plan 2015 Plan 2005 Plan Compensation based stock option activity for qualified and unqualified stock options are summarized as follows: Weighted Average Shares Exercise Price Outstanding at December 31, 2019 6,145,044 $ 0.75 Expired or canceled (15,040 ) 2.72 Outstanding at September 30, 2020 6,130,004 $ 0.75 The following table summarizes information about options to purchase shares of Mateon’s Common Stock outstanding and exercisable at September 30, 2020: Weighted- Weighted- Average Average Outstanding Remaining Life Exercise Number Exercise prices Options In Years Price Exercisable $ 0.22 2,524,513 7.73 $ 0.22 2,524,513 0.38 1,162,500 6.29 0.38 1,162,500 0.51 242,966 6.70 0.51 242,966 0.58 271,224 6.07 0.58 271,224 0.73 1,025,000 5.48 0.73 1,025,000 1.37 150,000 4.81 1.37 150,000 1.43 525,000 4.66 1.43 525,000 2.95 150,000 3.62 2.95 150,000 11.88 2,359 1.26 11.88 2,359 15.00 75,000 4.66 15.00 75,000 19.80 1,442 1.08 19.80 1,442 6,130,004 6.49 $ 0.75 6,130,004 The compensation expense attributed to the issuance of the options is recognized as they are vested. The employee stock option plan stock options are generally exercisable for ten years from the grant date and vest over various terms from the grant date to three years. The aggregate intrinsic value totaled $0 and was based on Mateon’s closing stock price of $0.18 as of September 30, 2020, which would have been received by the option holders had all option holders exercised their options as of that date. As of September 30, 2020, there was no future compensation cost as all stock options vested as the compensation was fully expensed prior to the Merger and no new options have been granted since then. In April 2019 and in conjunction with the close of the Merger, the Company recorded approximately $341,000 in compensation cost as a result of the acceleration of the vesting schedule of approximately 328,000 Oncotelic options. Pursuant to the Merger these options were converted into Common Stock and Series A Preferred Shares in the Company. In August 2019, the Company entered into Employment Agreements and incentive compensation arrangements with each of its executive officers, including Dr. Vuong Trieu, the Chief Executive Officer; Dr. Fatih Uckun, the Chief Medical Officer; Dr. Chulho Park, its Chief Technology Officer; and Mr. Amit Shah, the Chief Financial Officer. Details of the agreements and the incentive compensation is described in detail in Note 11 – Commitments & Contingencies under “Employment Agreements”. The incentive stock options or the restricted stock awards granted to the Company’s executive officers have not been granted as of the date of this filing. Warrants Pursuant to the Merger, Mateon’s Common Stock and corresponding outstanding warrants survived. The below information represents Mateon’s associated warrant activity pre-merger and post-merger. In February 2020, Mateon offered to cancel to all the prior warrants of the warrant holders from the 2018 debt financing and offered to reissue new warrants to such warrant holders. Out of all the warrant holders, holders of 13,750,000 warrants opted to participate in the reissuance. In addition, the Company issued 2,915,000 new warrants to certain accredited investors in connection with the financing through JH Darbie (See note 6). The issuance of warrants to purchase shares of Mateon’s Common Stock, including those attributed to debt issuances, as of September 30, 2020 and December 31, 2019 are summarized as follows: Weighted- Average As of September 30, 2020 Shares Exercise Price Outstanding at December 31, 2019 19,515,787 $ 0.60 Issued during the nine months ended September 30, 2020 16,665,000 0.20 Expired or cancelled (18,028,287 ) 0.63 Outstanding at September 30, 2020 18,152,500 $ 0.20 Weighted- As of December 31, 2019 Average Shares Exercise Price Outstanding at December 31, 2018 24,380,893 $ 1.05 Expired or cancelled (4,865,106 ) 2.82 Outstanding at December 31, 2019 19,515,787 $ 0.60 The following table summarizes information about warrants outstanding and exercisable at September 30, 2020: Outstanding and exercisable Weighted- Weighted- Average Average Number Remaining Life Exercise Number Exercise Price Outstanding in Years Price Exercisable $ 0.20 1,487,500 2.75 $ 0.20 1,487,500 0.20 2,915,000 3.00 0.20 - 0.20 13,750,000 2.75 0.20 13,750,000 18,152,500 2.75 $ 0.20 15,237,500 The expense attributed to the issuances of the warrants was recognized as they vested/earned. These warrants were exercisable for three to five years from the grant date. There were no warrants issued during the year ended December 31, 2019. 13,750,000 warrants were issued during the three months ended March 31, 2020 and Mateon recorded stock-based compensation of $2,100,000 as the fair value of the warrants using a Black Scholes valuation model using the following input values. Expected Term 3 years Expected volatility 140.5 % Risk-free interest rates 1.40 % Dividend yields 0.00 % As of the closing of the Company’s July through September private placement offering, the estimated grant date fair value of approximately $0.20 per share associated with the warrants to purchase up to 2,915,000 shares of common stock issued in this offering, or a total of approximately $0.4 million, was recorded to additional paid-in capital on a relative fair value basis. All warrants sold in this offering had an exercise price of $0.20 per share of the Company stock or $1.00 per share of Edge Point, subject to adjustment, are exercisable immediately and expire three years from the date of issuance. The fair value of the warrants was estimated using a Black Scholes valuation model using the following input values: Expected Term 1.5 years Expected volatility 184.7%-191.9 % Risk-free interest rates 0.13%-0.15 % Dividend yields 0.00 % The Company recorded an initial debt discount of approximately $0.6 million representing the intrinsic value of the conversion option embedded in the convertible debt instrument based upon the difference between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. The Company recognized amortization expense related to the debt discount and debt issuance costs of $162,267 for the three and nine months ended September 30, 2020 respectively, which is included in interest expense in the condensed statements of operations. No similar expense was recorded for the same periods in 2019.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 10 – INCOME TAXES The Company had gross deferred tax assets of approximately $66,100,000 and $65,000,000 as of September 30, 2020 and December 31, 2019, respectively, which primarily relate to net operating loss carryforwards. The increase during the nine months ended September 30, 2020 relates to the operations of the Company. The Company records a valuation allowance in the full amount of our net deferred tax assets since realization of such tax benefits has been determined by the Company’s management to be less likely than not. The Company has identified our federal and California state tax returns as “major” tax jurisdictions. Currently, the periods the Company’s income tax returns are subject to examination for these jurisdictions are 2015 through 2018, until such time the Company files the 2019 tax return. The Company believes its income tax filing positions and deductions will be sustained on audit, and the Company do not anticipate any adjustments that would result in a material change to its financial position. Therefore, no liabilities for uncertain income tax positions have been recorded. At September 30, 2020, the Company had available net operating loss carry forwards for federal income tax reporting purposes of approximately $251,700,000, including net operating losses of $3,700,000 recorded through the nine months ended September 30, 2020. At December 31, 2019, the Company had available net operating loss carry-forwards for federal income tax reporting purposes of approximately $248,000,000 which are available to offset future taxable income. Portions of these carry-forwards will expire through 2038 if not otherwise utilized. The Company has not performed a formal analysis, but the Company believes its ability to use such net operating losses and tax credit carry-forwards is subject to annual limitations due to change of control provisions under Sections 382 and 383 of the Internal Revenue Code, which significantly impacts the Company’s ability to realize these deferred tax assets. As of the date of this filing, the Company has not filed its 2019 federal and state corporate income tax returns. The Company expects to file these documents as soon as practicable.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 11 – COMMITMENTS AND CONTINGENCIES Leases Currently, the Company is leasing the office located at 29397 Agoura Road, Suite 107, Agoura Hills, CA 91301 on a month-to-month basis until such time a new office is identified. Legal Claims From time to time, the Company may become involved in legal proceedings arising in the ordinary course of business. The Company is not presently a party to any legal proceedings that it currently believes, if determined adversely to the Company, would individually or taken together have a material adverse effect on the Company’s business, operating results, financial condition or cash flows. Employment Agreements In August 2019, Mateon entered into Employment Agreements and incentive compensation arrangements with each of its then executive officers, including Dr. Vuong Trieu, the Chief Executive Officer; Dr. Fatih Uckun, the Chief Medical Officer; Dr. Chulho Park, the Chief Technology Officer; and Mr. Amit Shah, the Chief Financial Officer. In November 2019, upon review of the said employment agreement with Dr. Uckun, it was observed that the agreement submitted for Dr. Uckun was the incorrect document and the Company filed the correct document. The Employment Agreements provide for annual base salaries for each year of the term, subject to review and adjustment by Mateon’s Board or the Compensation Committee of the Board (the “ Compensation Committee The Employment Agreements provide for equity awards to each executive under the terms of Mateon’s stock option plans. Each Employment Agreement provides that the executive will receive a restricted stock grant of the Mateon’s Common Stock. Mateon will compensate Messrs. Trieu, Park and Shah for the taxes actually incurred on grant of the restricted shares. The restricted stock will vest fully on the one-year anniversary of employment. As of December 31, 2019, the restricted shares have yet to be issued. The Employment Agreements also provide for grants of incentive stock options to purchase shares of Mateon’s Common Stock under the Stock Plans. Such options shall vest and become exercisable after one year of employment. As of December 31, 2019, these options had yet to be granted. Thereafter, each Employment Agreement contemplates that the executive will be eligible to receive a comparable annual grant of restricted shares or stock options as approved by the Board or Compensation Committee and which shall contain the customary terms and provisions of such grants generally to key executives under the 2017 Stock Plan. The initial restricted stock grants and stock option grants have been set for the executives as follows: Executive Title Restricted Stock Stock Options Vuong Trieu Chief Executive Officer 209,302 313,953 Chulho Park Chief Technology Officer 162,791 244,186 Amit Shah Chief Financial Officer 148,837 223,256 The incentive stock options or the restricted stock awards granted to the Mateon’s officers have not been issued as of the date of this filing. PointR Merger Consideration The total purchase price of $17,831,427 represented the consideration transferred from Mateon in the PointR Merger and was calculated based on the number of shares of Common Stock plus the preferred shares outstanding but convertible into Common Stock outstanding at the date of the PointR Merger and includes $2,625,000 of contingent consideration of shares issuable to PointR shareholders upon achievement of certain milestones.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 12 – SUBSEQUENT EVENTS Change in Name On November 5, 2020, the Company filed an amendment to its Certificate of Incorporation with the Secretary of State for the State of Delaware changing its name from “Mateon Therapeutics, Inc.” to “Oncotelic Therapeutics, Inc.” A notice of corporate action has been filed with the Financial Industry Regulatory Authority (FINRA), requesting approval to change its name and ticker symbol. The Company is still awaiting FINRA’s approval on its notice of corporate action, and upon receipt of acceptance, the Company’s ticker symbol will be changed to reflect the Company’s name change. GMP Note In June 2020, Mateon secured $2 million in debt financing, evidenced by a one year convertible note (the “GMP Note”) from GMP, to conduct a clinical trial evaluating OT-101 against COVID-19 bearing 2% annual interest, and is personally guaranteed by Dr. Vuong Trieu, the Chief Executive Officer of Mateon. The GMP Note is convertible into Mateon’s Common Stock upon the GMP Note’s maturity one year from the date of the GMP Note, at Mateon’s Common Stock price on the date of conversion with no discount. GMP does not have the option to convert prior to the GMP Note’s maturity at the end of one year. Such financing will be utilized solely to fund the clinical trial. The Company’s liability under GMP Note commenced to accrue when GMP first began to pay for services related to the clinical trial to our third-party clinical research organization, up to a maximum of $2 million. In October 2020, the GMP paid approximately $0.5 million to the clinical trial organization, which accrued as a liability to the Company under the terms of the GMP Note. Consent Solicitation On June 25, 2020, the Company commenced a solicitation of shareholder consents (the “ Consent Solicitation Consent Solicitation Statement Stockholders (1) changing the name of the Company to “Oncotelic, Inc.” and to changing the Company’s ticker symbol (the “ Name Change (2) amending the Company’s Amended and Restated 2015 Equity Incentive Plan (the “ 2015 Plan Plan Amendment (3) increasing the authorized number of shares of Common Stock from 150,000,000 to 750,000,000 (the “ Capital Increase (4) amending and restating the certificate of incorporation for the Company (the “ Amended and Restated Certificate The Stockholders approved the Name Change, the Plan Amendment, the Capital Increase, and the Amended and Restated Certificate. The State of Delaware approved the name change on November 5, 2020. Entry into MOU and Commercialization Agreement with Windlas On August 19, 2020 the Company executed a memorandum of understanding (the “ MOU “Windlas On September 1, 2020 the Company executed the final MOU with Windlas regarding the development and commercialization of Artemisinin as therapeutic pharmaceutical, nutraceutical and herbal supplement against COVID-19. The ARTI-19 trial has been cleared by India regulatory authorities for initiation. The trial is now registered under CTRI and three sites have been selected, their IRB approval obtained, their staffs have been trained into the protocol/EDC. Additional sites will be added as the trial progressed. Enrollment of patients has already commenced for the trial. The Company and Windlas entered into a License, Development and Commercialization Agreement, dated November 10, 2020 (the “ Commercialization Agreement

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity-based transactions and disclosure of contingent liabilities at the date of the financial statements and revenues and expense during the reporting period. Actual results could materially differ from those estimates. The Company believes the following critical accounting policies affect its more significant judgments and estimates used in the preparation of the financial statements. Significant estimates include the valuation of goodwill and intangible assets for impairment, deferred tax asset and valuation allowance, and fair value of financial instruments.
Cash	Cash As of September 30, 2020, and December 31, 2019, the Company held all its cash in banks in the United States of America. The Company considers investments in highly liquid instruments with a maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents as of September 30, 2020 and December 31, 2019. Restricted cash consists of certificates of deposits held at banks as collateral for various purposes.
Investment in Equity Securities	Investment in Equity Securities Prior to the Merger, Oncotelic received Series E Preferred Shares of Adhera Therapeutics, Inc. (“ Adhera ASC ASC 321
Debt Issuance Costs and Debt Discount	Debt issuance Costs and Debt discount Issuance costs are specific incremental costs that are (1) paid to third parties and (2) directly attributable to the issuance of a debt or equity instrument. The issuance costs attributable to the initial sale of the instrument should be offset against the associated proceeds in the determination of the instrument’s initial net carrying amount. Debt issuance costs and debt discounts are being amortized over the lives of the related financings on a basis that approximates the effective interest method. Costs and discounts are presented as a reduction of the related debt in the accompanying condensed balance sheets if related to the issuance of debt or presented as a reduction of Additional Paid in capital if related to the issuance of an equity instrument. The Company applied the relative fair value to allocate the issuance costs among freestanding instruments that form part of the same transaction.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying value of cash, accounts payable and accrued expense approximate their fair values based on the short-term maturity of these instruments. As defined in ASC 820, “Fair Value Measurements and Disclosures,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent measurement. The three levels of the fair value hierarchy defined by ASC 820 are as follows: ● Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities. ● Level 2 – Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars. ● Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value. Other than the restricted cash of $20,000, the Company did not have any Level 1 or Level 2 assets and liabilities at September 30, 2020. Carrying Fair Value Measurement Using At September 30, 2020 Value Level 1 Level 2 Level 3 Total Restricted Cash – CDs at Bank $ 20,000 $ 20,000 $ - $ - $ 20,000 $ 20,000 $ - $ - $ - $ 20,000 The derivative liabilities associated with its 2019 convertible note debt /financing (see Note 5), consisted of conversion feature derivatives at September 30, 2020 hence are classified as Level 3 fair value measurements. The table below sets forth a summary of the changes in the fair value of the Company’s derivative liabilities classified as Level 3 as of September 30, 2020: Conversion Feature Balance at December 31, 2019 $ 540,517 New derivative liability 870,268 Reclassification to additional paid in capital from conversion of debt to common stock (573,811 ) Change in fair value (60,504 ) Balance at September 30, 2020 $ 776,470 As of September 30, 2020, and December 31, 2019, the Company estimated the fair value of the conversion feature derivatives embedded in the convertible debentures based on assumptions used in the Black-Scholes valuation model. The key valuation assumptions used consists, in part, of the price of the Company’s Common Stock, a risk free interest rate based on the yield of a Treasury note and expected volatility of the Company’s Common Stock all as of the measurement dates. The Company used the following assumptions to estimate fair value of the derivatives as of September 30, 2020: September 30, 2020 Risk free interest 0.13 % Market price of share $ 0.18 Life of instrument in years 1.56 – 1.85 Volatility 150.77 % Dividend yield 0 % When the Company changes its valuation inputs for measuring financial liabilities at fair value, either due to changes in current market conditions or other factors, it may need to transfer those liabilities to another level in the hierarchy based on the new inputs used. The Company recognizes these transfers at the end of the reporting period that the transfers occur. For the period ended September 30, 2020, there were no transfers of financial assets or financial liabilities between the hierarchy levels.
Other Fair Value Measurements	Other Fair Value Measurements As of the closing of the Company’s first three rounds of offering under a private placement memorandum with JH Darbie, the estimated grant date fair value of approximately $0.2 per share associated with the warrants to purchase up to 2,915,000 shares of common stock issued in this offering, or a total of approximately $0.4 million, was recorded to additional paid-in capital on a relative fair value basis. All warrants sold in this offering had an exercise price of $0.20 per share of the Company stock or $1.00 per share of Edge Point, subject to adjustment, are exercisable immediately and expire three years from the date of issuance. The fair value of the warrants was estimated using a Black Scholes valuation model using the following input values Expected Term 1.5 years Expected volatility 184.7%-191.9 % Risk-free interest rates 0.13%-0.15 % Dividend yields 0.00 %
Net Income (Loss) Per Share	Net Income (Loss) Per Share Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share includes the effect of Common Stock equivalents (notes convertible into Common Stock, stock options and warrants) when, under either the treasury or if-converted method, such inclusion in the computation would be dilutive. The following number of shares have been excluded from diluted loss since such inclusion would be anti-dilutive: Three and Nine Months Ended September 30, 2020 2019 Convertible notes 20,237,084 10,000,000 Stock options 6,130,004 6,145,044 Warrants 18,152,500 19,515,787 Potentially dilutive securities 44,519,588 35,660,831
Stock-Based Compensation	Stock-Based Compensation The Company applies the provisions of ASC 718, Compensation—Stock Compensation (“ ASC 718 For stock options issued to employees and members of the Board of Directors (the “ Board Pursuant to ASU 2018-07 Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, the Company accounts for stock options issued to non-employees for their services in accordance with ASC 718. The Company uses valuation methods and assumptions to value the stock options that are in line with the process for valuing employee stock options noted above. For warrants issued in connection with fund raising activities, the Company estimates the grant date fair value of each warrant using the Black-Scholes pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the warrant, the expected volatility of the Common Stock consistent with the expected life of the warrant, risk-free interest rates and expected dividend yields of the Common Stock. If the warrants are issued upon termination or cancellation of prior issued warrants, then the Company estimates the grant date fair value of the new warrants using the Black-Scholes pricing model and evaluates whether the new warrants are deemed as equity instruments or liability instruments. If the warrants are deemed to be equity instruments, the Company records stock compensation expense and an addition to additional paid in capital. If however, the warrants are deemed to be liability instruments, then the fair value is treated as a deemed dividend and credited to additional paid in capital.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews long-lived assets, including definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows or appraised values, depending on the nature of the assets. For the nine months ended September 30, 2020 and year ended December 31, 2019, there were no impairment losses recognized for long-lived assets.
Intangible Assets	Intangible Assets The Company records its intangible assets at cost in accordance with ASC 350, Intangibles – Goodwill and Other. The Company reviews the intangible assets for impairment on an annual basis or if events or changes in circumstances indicate it is more likely than not that they are impaired. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. If the review indicates the impairment, an impairment loss would be recorded for the difference of the value recorded and the new value. For the nine months ended September 30, 2020 and 2019, there were no impairment losses recognized for intangible assets.
Goodwill	Goodwill Goodwill represents the excess of the purchase price of acquired business over the estimated fair value of the identifiable net assets acquired. Goodwill is not amortized but is tested for impairment at least once annually, at the reporting unit level or more frequently if events or changes in circumstances indicate that the asset might be impaired. The goodwill impairment test is applied by performing a qualitative assessment before calculating the fair value of the reporting unit. If, on the basis of qualitative factors, it is considered not more likely than not that the fair value of the reporting unit is less than the carrying amount, further testing of goodwill for impairment would not be required. Otherwise, goodwill impairment is tested using a two-step approach. The first step involves comparing the fair value of the reporting unit to its carrying amount. If the fair value of the reporting unit is determined to be greater than its carrying amount, there is no impairment. If the reporting unit’s carrying amount is determined to be greater than the fair value, the second step must be completed to measure the amount of impairment, if any. The second step involves calculating the implied fair value of goodwill by deducting the fair value of all tangible and intangible assets, excluding goodwill, of the reporting unit from the fair value of the reporting unit as determined in step one. The implied fair value of the goodwill in this step is compared to the carrying value of goodwill. If the implied fair value of the goodwill is less than the carrying value of the goodwill, an impairment loss equivalent to the difference is recorded. For the nine months ended September 30, 2020 and 2019, there were no impairment losses recognized for Goodwill.
Convertible Instruments	Convertible Instruments The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with ASC 815 “Derivatives and Hedging”. ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur, and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Professional standards also provide an exception to this rule when the host instrument is deemed to be conventional as defined under professional standards as “The Meaning of Conventional Convertible Debt Instrument.” The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with ASC 470-20 “Debt – Debt with Conversion and Other Options.” Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying Common Stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Original issue discounts (“ OID ASC 815-40 “Derivatives and Hedging – Contracts in Entity’s Own Equity” provides that, among other things, generally, if an event occurs that is not within the entity’s control could or would require net cash settlement, then the contract shall be classified as an asset or a liability.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASU Under ASU 2014-9, the Company recognizes revenue when its customers obtain control of the promised good or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. The Company applies the following five-step process: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of ASU 2014-09, the Company identifies the performance obligation(s) in the contract by assessing whether the goods or services promised within each contract are distinct. The Company then recognizes revenue for the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The Company anticipates generating revenues from rendering services to other third party customers for the development of certain drug products and/or in connection with certain out-licensing agreements. In the case of services rendered for development of the drugs, revenue is recognized upon the achievement of the performance obligations or over time on a straight-line basis over the extended service period. In the case of out-licensing contracts, the Company records revenues either (i) upon achievement of certain pre-defined milestones when there is no obligation of the Company achieve any performance obligations in connection with the said pre-defined milestones, or (ii) upon achievement of the performance obligations if the milestones require the Company to provide the performance obligations. The Company occasionally collects advance payments from customers toward commitments to provide services or performance obligations, in which case the advance payment is recorded as a liability until the obligations are fulfilled and revenue is recognized.
Research Service Agreement between GMP and Mateon Therapeutics Inc./Oncotelic Inc. ("Mateon Entities").	Research Service Agreement between GMP and Mateon Therapeutics Inc./Oncotelic Inc. (“Mateon Entities”). In February 2020, Oncotelic and GMP entered into a research and services agreement (the “ Agreement Product Supplement
Agreement with Autotelic BIO	Agreement with Autotelic BIO Oncotelic had entered into a license agreement in February 2018 (the “ ATB Agreement Combined Product
Research & Development Costs	Research & Development Costs In accordance with ASC 730-10-25 “Research and Development”, research and development costs are charged to expense as and when incurred.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In January 2017, the Financial Accounting Standards Board (“ FASB ASU In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which defers the effective date of ASU 2014-09 for all entities by one year. ASU 2014-09 became effective on January 1, 2018. The ASU also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. The Company adopted ASU 2015-14 during the nine months ended September 30, 2020 as till then, no revenue was earned by the Company. In August 2020, the FASB issued “ASU 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)” which simplifies the accounting for convertible instruments. The guidance removes certain accounting models which separate the embedded conversion features from the host contract for convertible instruments. Either a modified retrospective method of transition or a fully retrospective method of transition is permissible for the adoption of this standard. Update No. 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted no earlier than the fiscal year beginning after December 15, 2020. The Company is currently evaluating the potential impact of the Update on its financial statements All other newly issued but not yet effective accounting pronouncements have been deemed to be not applicable or immaterial to the Company.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Schedule of Assets and Liabilities	Other than the restricted cash of $20,000, the Company did not have any Level 1 or Level 2 assets and liabilities at September 30, 2020. Carrying Fair Value Measurement Using At September 30, 2020 Value Level 1 Level 2 Level 3 Total Restricted Cash – CDs at Bank $ 20,000 $ 20,000 $ - $ - $ 20,000 $ 20,000 $ - $ - $ - $ 20,000
Summary of Changes in Fair Value of Derivative Liabilities	The table below sets forth a summary of the changes in the fair value of the Company’s derivative liabilities classified as Level 3 as of September 30, 2020: Conversion Feature Balance at December 31, 2019 $ 540,517 New derivative liability 870,268 Reclassification to additional paid in capital from conversion of debt to common stock (573,811 ) Change in fair value (60,504 ) Balance at September 30, 2020 $ 776,470
Summary of Estimate Fair Value of Derivative Liabilities	The Company used the following assumptions to estimate fair value of the derivatives as of September 30, 2020: September 30, 2020 Risk free interest 0.13 % Market price of share $ 0.18 Life of instrument in years 1.56 – 1.85 Volatility 150.77 % Dividend yield 0 %
Schedule of Fair Value Warrants Estimated Using Black Scholes Valuation Model	The fair value of the warrants was estimated using a Black Scholes valuation model using the following input values Expected Term 1.5 years Expected volatility 184.7%-191.9 % Risk-free interest rates 0.13%-0.15 % Dividend yields 0.00 %
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following number of shares have been excluded from diluted loss since such inclusion would be anti-dilutive: Three and Nine Months Ended September 30, 2020 2019 Convertible notes 20,237,084 10,000,000 Stock options 6,130,004 6,145,044 Warrants 18,152,500 19,515,787 Potentially dilutive securities 44,519,588 35,660,831

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2020
Schedule of Intangible Assets	The following table summarizes the balances as of September 30, 2020 and December 31, 2019, of the intangible assets acquired, their useful life, and annual amortization: September 30, 2020 Remaining Estimated Useful Life (Years) Intangible asset – Intellectual Property $ 819,191 18.26 Intangible asset – Capitalization of license cost 190,989 18.26 1,010,180 Less Accumulated Amortization (124,133 ) Total $ 886,047 December 31, 2019 Remaining Estimated Useful Life (Years) Intangible asset – Intellectual Property $ 819,191 18.68 Intangible asset – Capitalization of license cost 190,989 18.68 1,010,180 Less Accumulated Amortization (85,608 ) Total $ 924,572
Schedule of Amortization of Expense for Intangible Assets	The future yearly amortization expense over the next five years and thereafter are as follows: For the years ended December 31, Remainder of 2020 $ 12,841 2021 51,365 2022 51,365 2023 51,365 2024 51,365 Thereafter 667,746 $ 886,047
In Process Research and Development [Member]
Schedule of Intangible Assets	The following table summarizes the balances as of September 30, 2020 of the IPR&D assets acquired during the three months ended December 31, 2019. The Company will evaluate, on an annual basis, for any impairment and record an impairment if identified. No similar balances were present in 2019: September 30, 2020 Remaining Estimated Useful Life (Years) Intangible asset – Intellectual Property $ 1,377,200 4.25 1,377,200 Less Accumulated Amortization (206,580 ) Total $ 1,170,620
Schedule of Amortization of Expense for Intangible Assets	The future yearly amortization expense over the next five years and thereafter are as follows: For the years ended December 31, Remainder of 2020 $ 68,860 2021 275,440 2022 275,440 2023 275,440 2024 275,440 $ 1,170,620

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2020
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Expenses	Accounts payable and accrued expense consists of the following amounts: September 30, 2020 December 31, 2019 Accounts payable $ 2,024,261 $ 1,793,033 Accrued expense 707,359 261,950 $ 2,731,620 $ 2,054,983 September 30, 2020 December 31, 2019 Accounts payable – related party $ 385,002 $ 601,682

Convertible Debentures. Notes_2

Convertible Debentures. Notes and Other Debt (Tables)	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Schedule of Convertible Debentures	As of September 30, 2020, SPAs with convertible debentures and notes, net of debt discount, consist of the following amounts: September 30, 2020 Convertible debentures 10% Convertible note payable, due June 12, 2022 – Peak One $ 11,183 10% Convertible note payable, due April 23, 2022 - TFK 33,823 10% Convertible note payable, due April 23, 2022 – Related Party 10,197 10% Convertible note payable, due April 23, 2022 – Bridge Investor 51,817 10% Convertible note payable, due August 6, 2022 – Bridge Investor 163,485 270,505 Fall 2019 Notes 5% Convertible note payable – Stephen Boesch 250,648 5% Convertible note payable – Related Party 250,477 5% Convertible note payable – Dr. Sanjay Jha (Through his family trust) 249,997 5% Convertible note payable – CEO, CTO & CFO 84,268 5% Convertible note payable – Bridge Investors 172,647 1,008,037 Other Debt Short term debt from CEO 70,000 Total of debentures, notes and other debt $ 1,348,542 As of December 31, 2019, convertible debentures and notes, net of debt discount, consist of the following amounts: December 31, 2019 10% Convertible note payable, due April 23, 2022 – Peak One $ 115,623 10% Convertible note payable, due June 12, 2022 – Peak One (81,735 ) 10% Convertible note payable, due April 23, 2022 - TFK 115,623 10% Convertible note payable, due April 23, 2022 – Related Party (12,663 ) 10% Convertible note payable, due April 23, 2022 – Bridge Investor (2,748 ) 10% Convertible note payable, due August 6, 2022 – Bridge Investor 26,824 160,924 Fall 2019 Notes 5% Convertible note payable – Stephen Boesch 187,785 5% Convertible note payable – Vuong Trieu* 187,785 5% Convertible note payable – Sanjay Jha (Through his family trust) 187,785 5% Convertible note payable – CEO, CTO & CFO 77,620 5% Convertible note payable – Bridge Investors 159,025 800,000 Total of notes and other debt $ 960,924

Private Placement and JH Darb_2

Private Placement and JH Darbie Financing (Tables)	9 Months Ended
	Sep. 30, 2020
Private Placement And Jh Darbie Financing
Schedule of Funds Received Under the Subscription Agreement	As of September 30, 2020, funds received under the JH Darbie Financing, net of debt discount, consist of the following amounts: September 30, 2020 Convertible promissory notes Subscription agreements - accredited investors $ 612,892 Subscription agreements – related party 33,274 Total convertible promissory notes $ 646,166

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2020
Schedule of Compensation Based Stock Option Activity	Compensation based stock option activity for qualified and unqualified stock options are summarized as follows: Weighted Average Shares Exercise Price Outstanding at December 31, 2019 6,145,044 $ 0.75 Expired or canceled (15,040 ) 2.72 Outstanding at September 30, 2020 6,130,004 $ 0.75
Schedule of Options to Purchase Shares of Common Stock Outstanding and Exercisable	The following table summarizes information about options to purchase shares of Mateon’s Common Stock outstanding and exercisable at September 30, 2020: Weighted- Weighted- Average Average Outstanding Remaining Life Exercise Number Exercise prices Options In Years Price Exercisable $ 0.22 2,524,513 7.73 $ 0.22 2,524,513 0.38 1,162,500 6.29 0.38 1,162,500 0.51 242,966 6.70 0.51 242,966 0.58 271,224 6.07 0.58 271,224 0.73 1,025,000 5.48 0.73 1,025,000 1.37 150,000 4.81 1.37 150,000 1.43 525,000 4.66 1.43 525,000 2.95 150,000 3.62 2.95 150,000 11.88 2,359 1.26 11.88 2,359 15.00 75,000 4.66 15.00 75,000 19.80 1,442 1.08 19.80 1,442 6,130,004 6.49 $ 0.75 6,130,004
Schedule of Warrants Activity	The issuance of warrants to purchase shares of Mateon’s Common Stock, including those attributed to debt issuances, as of September 30, 2020 and December 31, 2019 are summarized as follows: Weighted- Average As of September 30, 2020 Shares Exercise Price Outstanding at December 31, 2019 19,515,787 $ 0.60 Issued during the nine months ended September 30, 2020 16,665,000 0.20 Expired or cancelled (18,028,287 ) 0.63 Outstanding at September 30, 2020 18,152,500 $ 0.20 Weighted- As of December 31, 2019 Average Shares Exercise Price Outstanding at December 31, 2018 24,380,893 $ 1.05 Expired or cancelled (4,865,106 ) 2.82 Outstanding at December 31, 2019 19,515,787 $ 0.60
Schedule of Warrants Outstanding and Exercisable	The following table summarizes information about warrants outstanding and exercisable at September 30, 2020: Outstanding and exercisable Weighted- Weighted- Average Average Number Remaining Life Exercise Number Exercise Price Outstanding in Years Price Exercisable $ 0.20 1,487,500 2.75 $ 0.20 1,487,500 0.20 2,915,000 3.00 0.20 - 0.20 13,750,000 2.75 0.20 13,750,000 18,152,500 2.75 $ 0.20 15,237,500
Schedule of Black Scholes Valuation Allowance Model of Warrants	Expected Term 3 years Expected volatility 140.5 % Risk-free interest rates 1.40 % Dividend yields 0.00 %
Private Placement [Member]
Schedule of Black Scholes Valuation Allowance Model of Warrants	The fair value of the warrants was estimated using a Black Scholes valuation model using the following input values: Expected Term 1.5 years Expected volatility 184.7%-191.9 % Risk-free interest rates 0.13%-0.15 % Dividend yields 0.00 %

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Summary of Restricted Stock Grants and Stock Option Grants	The initial restricted stock grants and stock option grants have been set for the executives as follows: Executive Title Restricted Stock Stock Options Vuong Trieu Chief Executive Officer 209,302 313,953 Chulho Park Chief Technology Officer 162,791 244,186 Amit Shah Chief Financial Officer 148,837 223,256

Description of Business and B_2

Description of Business and Basis of Presentation (Details Narrative) - USD ($)	Oct. 30, 2020	Jun. 30, 2020	Feb. 25, 2020	Apr. 30, 2019	Sep. 30, 2020	Aug. 31, 2020	Jul. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Jun. 25, 2020	Jun. 24, 2020
Proceeds from private placement															$ 2,304,541
Common stock, par value					$ 0.01			$ 0.01						$ 0.01	$ 0.01
Common stock, shares authorized					150,000,000			150,000,000						150,000,000	150,000,000
Net losses								$ (1,986,557)	$ 582,091	$ (4,657,894)	$ (991,126)	$ (1,189,110)	$ (976,063)		$ (6,062,360)	(3,156,299)
Working capital					$ (7,300,000)			(7,300,000)							(7,300,000)
Contingent liability					2,600,000			2,600,000							2,600,000
Service Revenue															1,740,855
Common Stock [Member]
Net losses
GMP Note [Member]
Debt financing		$ 2,000,000							$ 2,000,000
Debt term		1 year
Interest rate		2.00%							2.00%
GMP Note [Member] | Subsequent Event [Member]
Cash paid to clinical trial organization	$ 500,000
Vuong Trieu, CEO [Member]
Funded amount					70,000			70,000							$ 70,000
JH Darbie & Co., Inc. [Member]
Proceeds from private placement					$ 2,650,000		$ 2,650,000	$ 2,300,000
Number of shares issued and sold					53	53	53	25,000
Common stock, par value					$ 0.01			$ 0.01							$ 0.01
Sale of stock price per share					1			$ 1							1
Debt conversion of convertible shares								138,889
Conversion price per share					$ 0.18			$ 0.18							$ 0.18
Placement agent fees					$ 300,000		$ 400,000
JH Darbie & Co., Inc. [Member] | Minimum [Member]
Number of shares issued and sold			40
JH Darbie & Co., Inc. [Member] | Maximum [Member]
Number of shares issued and sold			100
JH Darbie & Co., Inc. [Member] | Warrants [Member]
Number of warrant to purchase shares of common stock					100,000			100,000							100,000
JH Darbie & Co., Inc. [Member] | Edgepoint Warrant [Member]
Number of warrant to purchase shares of common stock					50,000			50,000							50,000
Warrant exercise price per share					$ 1			$ 1							$ 1
JH Darbie & Co., Inc. [Member] | Mateon Warrant [Member]
Number of warrant to purchase shares of common stock					50,000			50,000							50,000
Warrant exercise price per share					$ 0.20			$ 0.20							$ 0.20
GMP and Autotelic BIO [Member]
Service Revenue															$ 1,700,000
Supplemental Agreement [Member] | Oncotelic, Inc. [Member]
Payment for services		$ 500,000
Supplemental Agreement [Member] | GMP Note Liability [Member]
Payment for services		500,000
Debt financing		2,000,000							$ 2,000,000
Supplemental Agreement [Member] | Golden Mountain Partners LLC [Member]
Payment for services				$ 1,200,000
Supplemental Agreement [Member] | Golden Mountain Partners LLC [Member] | Vuong Trieu [Member]
Debt financing		$ 2,000,000							$ 2,000,000
Debt term		1 year
Interest rate		2.00%							2.00%
Darbie Placement Agreement [Member] | JH Darbie & Co., Inc. [Member]
Proceeds from private placement			$ 400,000
Payment of direct placement fees			$ 300,000
Sale of units description			Under the Darbie Placement Agreement, JH Darbie has the right to sell a minimum of 40 Units, as described in Note 6 below, and a maximum of 100 Units on a best-efforts basis. The issuance and sale of the 53 Units in July, August and September 2020 represented the first three tranches of the JH Darbie Financing. JH Darbie also earned the right to 5.3 Units as their fees.
Restated 2015 Equity Incentive Plan [Member] | Common Stock [Member]
Increase the number of shares of Common Stock available for issuance																	27,250,000	7,250,000
Increasing the maximum number of stock awards																	1,000,000	500,000
Common stock, shares authorized																	750,000,000	150,000,000
Since Inception Date [Member]
Net losses															18,200,000
Assumed working capital					$ (1,300,000)			$ (1,300,000)							$ (1,300,000)
Securities Purchase Agreement [Member] | Two Notes Payable [Member]
Proceeds from notes payable														$ 2,000,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Cash equivalents
Restricted cash	20,000				20,000
Additional paid-in capital	32,176,064				32,176,064		28,185,599
Impairment losses on long-lived assets
Impairment losses on intangible assets
Impairment losses on goodwill
Reimbursement of actual costs					40,000
Revenue					1,740,855
in-Vivo [Member]
Revenue					500,000
Oncotelic, Inc. [Member]
Due to related parties	$ 500,000				500,000
ATB Agreement [Member] | Japan, China, Brazil, Mexico, Russia and Korea [Member]
Marketing approval received value					1,000,000
ATB Agreement [Member] | Germany, France, Spain, Italy and UK [Member]
Marketing approval received value					$ 2,000,000
JH Darbie & Co., Inc. [Member] | Warrants [Member]
Warrants to purchase common stock	100,000				100,000
Golden Mountain Partners LLC [Member] | Research Service Agreement [Member]
Service fees		$ 900,000	$ 300,000
Autotelic BIO [Member] | ATB Agreement [Member]
Revenue					$ 500,000
Private Placement [Member]
Warrant exercise price per share	$ 0.20				$ 0.20
Private Placement [Member] | JH Darbie & Co., Inc. [Member] | Warrants [Member]
Fair value per share	$ 0.2				$ 0.2
Warrants to purchase common stock	2,915,000				2,915,000
Additional paid-in capital	$ 400,000				$ 400,000
Warrant exercise price per share	$ 0.20				$ 0.20

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Assets and Liabilities (Details)	Sep. 30, 2020USD ($)
Assets and liabilities	$ 20,000
Carrying value	20,000
Level 1 [Member]
Assets and liabilities
Level 2 [Member]
Assets and liabilities
Level 3 [Member]
Assets and liabilities
Restricted Cash - CDs at Bank [Member]
Assets and liabilities	20,000
Carrying value	20,000
Restricted Cash - CDs at Bank [Member] | Level 1 [Member]
Assets and liabilities	20,000
Restricted Cash - CDs at Bank [Member] | Level 2 [Member]
Assets and liabilities
Restricted Cash - CDs at Bank [Member] | Level 3 [Member]
Assets and liabilities

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Summary of Changes in Fair Value of Derivative Liabilities (Details)	9 Months Ended
	Sep. 30, 2020USD ($)
Accounting Policies [Abstract]
Beginning balance	$ 540,517
New derivative liability	870,268
Reclassifications to additional paid in capital from conversion of debt to common stock	(573,811)
Change in fair value	(60,504)
Closing balance	$ 776,470

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Summary of Estimate Fair Value of Derivative Liabilities (Details)	9 Months Ended
	Sep. 30, 2020$ / shares
Market price per share	$ 0.18
Risk Free Interest Rate [Member]
Derivative liability, measurement input	0.13
Life of Instrument in Years [Member] | Minimum [Member]
Derivative liability, measurement input term	1 year 6 months 21 days
Life of Instrument in Years [Member] | Maximum [Member]
Derivative liability, measurement input term	1 year 10 months 6 days
Volatility [Member]
Derivative liability, measurement input	150.77
Dividend Yield [Member]
Derivative liability, measurement input	0

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Schedule of Fair Value Warrants Estimated Using Black Scholes Valuation Model (Details) - Warrants [Member]	9 Months Ended
	Sep. 30, 2020
Expected Term	1 year 6 months
Dividend yields	0.00%
Minimum [Member]
Expected volatility	184.70%
Risk-free interest rates	0.13%
Maximum [Member]
Expected volatility	191.90%
Risk-free interest rates	0.15%

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Potentially dilutive securities	44,519,588	35,660,831	44,519,588	35,660,831
Convertible Notes [Member]
Potentially dilutive securities	20,237,084	10,000,000	20,237,084	10,000,000
Stock Options [Member]
Potentially dilutive securities	6,130,004	6,145,044	6,130,004	6,145,044
Warrant [Member]
Potentially dilutive securities	18,152,500	19,515,787	18,152,500	19,515,787

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended		9 Months Ended
		Apr. 30, 2018	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Aug. 31, 2019
Goodwill			$ 21,062,455		$ 21,062,455		$ 21,062,455
Amortization of identifiable intangible assets			12,841	$ 12,841	245,104	$ 38,524
In Process Research and Development [Member]
Amortization of identifiable intangible assets			68,860	$ 0	206,580	$ 0
Merger Agreement [Member] | PointR [Member]
Goodwill	[1]							$ 16,182,456
Merger Agreement [Member] | Oncotelic [Member]
Goodwill			$ 4,879,999		$ 4,879,999
Assignment and Assumption Agreement [Member] | Autotelic Inc., [Member]
Shares issued during the period for acquisition, shares		204,798
Shares issued during the period for acquisition		$ 819,191
[1]	The primary items that generate goodwill include the value of the synergies between the acquired company and PointR and the acquired assembled workforce, neither of which qualifies for recognition as an intangible asset.Goodwill is the excess of the purchase price over the fair value of the underlying net tangible and identifiable intangible assets. In accordance with applicable accounting standards, goodwill is not amortized but instead is tested for impairment at least annually or more frequently if certain indicators are present. Goodwill and intangibles is not deductible for tax purposes.

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Intangible asset, gross	$ 1,010,180	$ 1,010,180
Less Accumulated Amortization	(124,133)	(85,608)
Intangible asset, net	886,047	924,572
Intellectual Property [Member]
Intangible asset, gross	$ 819,191	$ 819,191
Remaining estimated useful life (years)	18 years 3 months 4 days	18 years 8 months 5 days
Capitalization of License Cost [Member]
Intangible asset, gross	$ 190,989	$ 190,989
Remaining estimated useful life (years)	18 years 3 months 4 days	18 years 8 months 5 days
Intellectual Property [Member]
Intangible asset, gross	$ 1,377,200
Remaining estimated useful life (years)	4 years 2 months 30 days
In Process Research and Development [Member]
Intangible asset, gross	$ 1,377,200
Less Accumulated Amortization	(206,580)	$ 0
Intangible asset, net	$ 1,170,620

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Schedule of Amortization of Expense for Intangible Assets (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Remainder of 2020	$ 12,841
2021	51,365
2022	51,365
2023	51,365
2024	51,365
Thereafter	667,746
Intangible asset, net	886,047	$ 924,572
In Process Research and Development [Member]
Remainder of 2020	68,860
2021	275,440
2022	275,440
2023	275,440
2024	275,440
Intangible asset, net	$ 1,170,620

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Accounts payable	$ 2,024,261	$ 1,793,033
Accrued expense	707,359	261,950
Accounts payable and accrued liabilities	2,731,620	2,054,983
Accounts payable - related party	$ 385,002	$ 601,682

Convertible Debentures. Notes_3

Convertible Debentures. Notes and Other Debt (Details Narrative) - USD ($)	Nov. 05, 2019	Nov. 05, 2019	Aug. 06, 2019	Jun. 12, 2019	Apr. 23, 2019	Apr. 23, 2019	Apr. 17, 2019	Apr. 30, 2020	Dec. 31, 2019	Nov. 30, 2019	Jul. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Nov. 30, 2020	Apr. 30, 2019
Debt Instrument [Line Items]
Convertible notes gross												$ 1,000,000		$ 1,000,000
Initial debt discount												800,140		800,140
Amortization expense related to debt discount														611,681	$ 88,479
Total unamortized debt discount									$ 173,175			321,290		321,290		$ 173,175
Derivative liability									541,000			776,000		776,000		541,000
Chance in fair value of derivative liability												49,992		60,504		870,268
Amortization of OID and debt issuance costs														1,591,261	88,479
Non-cash compensation expense														2,147,591	340,674
Accrued interest														1,008,037		1,003,870
TFK Investments, LLC [Member]
Debt Instrument [Line Items]
Principal amount												66,570		$ 66,570
Conversion of debt, shares														1,950,000
Conversion of debt, amount														$ 133,430
Series A Preferred Stock [Member] | PointR Shareholders [Member]
Debt Instrument [Line Items]
Accrued interest										$ 4,603
Shares conversion										84,475
Tranche One [Member] | Peak One Opportunity Fund, L.P [Member]
Debt Instrument [Line Items]
Conversion of debt, shares														2,581,945
Conversion of debt, amount														$ 200,000
Tranche Two [Member] | Peak One Opportunity Fund, L.P [Member]
Debt Instrument [Line Items]
Conversion of debt, shares														1,000,000
Conversion of debt, amount														$ 100,000
Fall 2019 Debt Financing [Member]
Debt Instrument [Line Items]
Gross proceeds from convertible debt									1,000,000
Additional gross proceeds from convertible debt									500,000
Fall 2019 Notes [Member] | Note Purchase Agreements [Member]
Debt Instrument [Line Items]
Total unamortized debt discount												88,888		88,888
Debt instrument, conversion description																	(a) into shares of the Company's Common Stock at a conversion price of $0.18 per share, or (b) into shares of common stock of the Company's newly formed subsidiary, EdgePoint AI, Inc., a Delaware Corporation, for AI/Blockchain in pharmaceutical manufacturing ("EdgePoint AI"), at a conversion price of $5.00 (based on a $5.0 million pre-money valuation) of EdgePoint AI and 1,000,000 shares outstanding.
Beneficial conversion feature, total																222,222
Amortization of OID and debt issuance costs												55,556	$ 0	111,112	$ 0
Debt interest rate										5.00%
Description on debt instrument																	All amounts outstanding under the Fall 2019 Notes become due and payable upon the approval of the holders of a majority of the principal amount of outstanding Fall 2019 Notes (the "Majority Holders") on or after (a) November 23, 2020 or (b) the occurrence of an event of default (either, the "Maturity Date"). The Company may prepay the Fall 2019 Notes at any time. Events of default under the Fall 2019 Notes include failure to make payments under the Fall 2019 Notes within thirty (30) days of the date due, failure to observe of the Fall 2019 Note Purchase Agreement or Fall 2019 Notes which is not cured within thirty (30) days of notice of the breach, bankruptcy, or a change in control of the Company (as defined in the Fall 2019 Note Purchase Agreement).
Interest expense												12,500		37,500
Convertible Debt [Member]
Debt Instrument [Line Items]
Initial debt discount												258,070		258,070
Total unamortized debt discount												232,054		232,054
Derivative liability									573,800							573,800
Chance in fair value of derivative liability														776,000		60,504
Convertible Debt [Member] | Peak One Opportunity Fund, L.P [Member] | Purchase Agreement [Member]
Debt Instrument [Line Items]
Total unamortized debt discount												0		0
Beneficial conversion feature, total							$ 84,570
Percentage of conversion price, description							(i) a conversion price, during the first 180 days, of $0.10 per share (the "Fixed Price"), and then (2) at the lower of the Fixed Price or 65% of the Company's lowest traded price after the first 180 days or at the lower of the Fixed Price or 55% of the Company's traded stock price under certain circumstances. The Company has agreed to at all times, reserve and keep available out of its authorized Common Stock a number of shares equal to at least two times the full number of the Tranche #1 Conversion Shares. The Company may redeem the Convertible Note at rates of 110% to 140% over the principal balance dependent on certain events and redeem the value with accrued interest thereon, if any.
Principal amount							$ 200,000
Aggregate purchase price							$ 400,000
Number of restricted stock issued							350,000
Maturity date							Apr. 23, 2022
Original issue discount, percentage							10.00%
Original issue discount							$ 20,000
Deferred financing costs							5,000
Net proceeds from convertible debt							175,000
Beneficial conversion feature, excluding discount							52,285
Number of restricted stock issued, value							32,285
Amortization of OID and debt issuance costs														84,376
Convertible Debt [Member] | Peak One Opportunity Fund, L.P [Member] | Purchase Agreement [Member] | Maximum [Member]
Debt Instrument [Line Items]
Principal amount							$ 400,000
Percentage of charge on penalty							40.00%
Percentage of redemption of convertible note							140.00%
Convertible Debt [Member] | Peak One Opportunity Fund, L.P [Member] | Purchase Agreement [Member] | Minimum [Member]
Debt Instrument [Line Items]
Percentage of charge on penalty							18.00%
Percentage of redemption of convertible note							110.00%
Convertible Debt [Member] | Peak One Opportunity Fund, L.P [Member] | Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Principal amount												100,000		100,000
Convertible Debt [Member] | TFK Investments, LLC [Member] | Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Total unamortized debt discount												3,589		3,589
Beneficial conversion feature, total					$ 84,570
Percentage of conversion price, description					(i) a conversion price, during the first 180 days, of $0.10 per share (the "Fixed Price"), and then (2) at the lower of the Fixed Price or 65% of the Company's lowest traded price after the first 180 days or at the lower of the Fixed Price or 55% of the Company's traded stock price under certain circumstances. The Company has agreed to at all times reserve and keep available out of its authorized Common Stock a number of shares equal to at least two times the full number of the TFK Conversion Shares. The Company may redeem the Convertible Note at rates of 110% to 140% rates over the principal balance dependent on certain events and redeem the value with accrued interest thereon, if any.
Principal amount					$ 200,000	$ 200,000
Number of restricted stock issued					350,000
Maturity date	Jan. 8, 2020				Apr. 23, 2022
Original issue discount, percentage					10.00%
Original issue discount					$ 20,000	20,000
Deferred financing costs					5,000	5,000
Net proceeds from convertible debt					175,000
Beneficial conversion feature, excluding discount					52,285
Number of restricted stock issued, value					$ 32,285
Amortization of OID and debt issuance costs														80,788
Conversion of debt, shares	300,000
Common stock percentage	65.00%	65.00%
Conversion price per share	$ 0.10	$ 0.10
Non-cash compensation expense	$ 60,000
Convertible Debt [Member] | TFK Investments, LLC [Member] | Securities Purchase Agreement [Member] | Maximum [Member]
Debt Instrument [Line Items]
Percentage of charge on penalty					40.00%
Percentage of redemption of convertible note					140.00%
Convertible Debt [Member] | TFK Investments, LLC [Member] | Securities Purchase Agreement [Member] | Minimum [Member]
Debt Instrument [Line Items]
Percentage of charge on penalty					18.00%
Percentage of redemption of convertible note					110.00%
Convertible Debt [Member] | PointR Data, Inc [Member]
Debt Instrument [Line Items]
Principal amount											$ 200,000
Maturity date											Jan. 1, 2020
Net proceeds from convertible debt											$ 10,000,000
Debt interest rate											8.00%
Debt instrument, payment terms											Interest payments were due monthly on the 15th day of each calendar month (or the next business day thereafter), and were payable, at the option of PointR, either in cash or in shares of Mateon's Common Stock, valued at the closing price of the Common Stock on the principal market on which the Common Stock is either traded or quoted at such time. The PointR Convertible Note was due and payable on demand by PointR (a) at any time after January 1, 2020 or (b) upon the occurrence of an Event of Default (as defined in the PointR Convertible Note and the PointR Note Purchase Agreement).
Convertible Debt [Member] | Tranche One [Member] | Peak One Opportunity Fund, L.P [Member]
Debt Instrument [Line Items]
Maturity date		Jan. 18, 2020
Conversion of debt, shares		300,000
Common stock percentage	65.00%	65.00%
Non-cash compensation expense		$ 60,000
Convertible Debt [Member] | Tranche One [Member] | Peak One Opportunity Fund, L.P [Member] | Purchase Agreement [Member] | Maximum [Member]
Debt Instrument [Line Items]
Principal amount				$ 600,000
Convertible Debt [Member] | Third Tranche [Member] | Peak One Opportunity Fund, L.P [Member] | Purchase Agreement [Member]
Debt Instrument [Line Items]
Principal amount				200,000
Convertible Debt [Member] | Tranche Two [Member] | Peak One Opportunity Fund, L.P [Member] | Purchase Agreement [Member]
Debt Instrument [Line Items]
Total unamortized debt discount												127,768		127,768
Beneficial conversion feature, total				180,000
Principal amount				$ 200,000
Number of restricted stock issued				350,000
Maturity date				Jun. 12, 2022
Original issue discount, percentage				10.00%
Original issue discount				$ 20,000
Deferred financing costs				1,000
Net proceeds from convertible debt				179,000
Beneficial conversion feature, excluding discount				132,091
Number of restricted stock issued, value				$ 47,909
Amortization of OID and debt issuance costs														36,187
Bridge Investor [Member] | Convertible Debt [Member] | Securities Purchase Agreement [Member] | Maximum [Member]
Debt Instrument [Line Items]
Principal amount							$ 400,000
Bridge Investor [Member] | Convertible Debt [Member] | Peak One and TFK Financing [Member]
Debt Instrument [Line Items]
Derivative liability									$ 541,000			870,000		870,000		$ 541,000
Beneficial conversion feature, total														232,000
Chance in fair value of derivative liability														$ 60,500
Percentage of conversion price, description														As as such, all the noteholders had the ability to convert that debt into equity at the variable conversion price of 65% of the Company's lowest traded price after the first 180 days or at the lower of the Fixed Price or 55% of the Company's traded stock price under certain circumstances.
Bridge Investor [Member] | Convertible Debt [Member] | Peak One and TFK Financing [Member] | Common Stock [Member]
Debt Instrument [Line Items]
Derivative liability												574,000		$ 574,000
Bridge Investor [Member] | Bifurcation of the Embedded Conversion Option [Member] | Peak One and TFK Financing [Member]
Debt Instrument [Line Items]
Beneficial conversion feature, total														258,070
Vuong Trieu [Member] | Convertible Debt [Member] | Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Total unamortized debt discount												8,568		$ 8,568
Principal amount					$ 164,444	164,444												$ 164,444
Original issue discount, percentage														10.00%
Original issue discount					16,444	$ 16,444												$ 16,444
Net proceeds from convertible debt					148,000
Amortization of OID and debt issuance costs														$ 4,095
Vuong Trieu [Member] | Convertible Debt [Member] | Securities Purchase Agreement [Member] | Bridge Investor [Member]
Debt Instrument [Line Items]
Beneficial conversion feature, total					$ 131,555
Percentage of conversion price, description					(i) a conversion price, during the first 180 days, of $0.10 per share (the "Fixed Price"), and then (2) at the lower of the Fixed Price or 65% of the Company's lowest traded price after the first 180 days or at the lower of the Fixed Price or 55% of the Company's traded stock price under certain circumstances. The Company may redeem the Convertible Note at rates of 110% to 140% rates over the principal balance dependent on certain events and redeem the value with accrued interest thereon, if any.
Maturity date					Apr. 23, 2022
Original issue discount, percentage					10.00%
Net proceeds from convertible debt					$ 148,000
Vuong Trieu [Member] | Convertible Debt [Member] | Securities Purchase Agreement [Member] | Maximum [Member]
Debt Instrument [Line Items]
Percentage of charge on penalty						40.00%
Percentage of redemption of convertible note						140.00%
Vuong Trieu [Member] | Convertible Debt [Member] | Securities Purchase Agreement [Member] | Minimum [Member]
Debt Instrument [Line Items]
Percentage of charge on penalty						18.00%
Percentage of redemption of convertible note						110.00%
Dr. Vuong Trieu [Member] | Fall 2019 Notes [Member] | Note Purchase Agreements [Member]
Debt Instrument [Line Items]
Principal amount										$ 250,000
Gross proceeds from convertible debt										500,000
Due to related parties										35,000
Stephen Boesch [Member] | Fall 2019 Notes [Member] | Note Purchase Agreements [Member]
Debt Instrument [Line Items]
Principal amount										250,000
Gross proceeds from convertible debt										500,000
Due to related parties										35,000
Dr. Sanjay Jha [Member] | Fall 2019 Notes [Member] | Note Purchase Agreements [Member]
Debt Instrument [Line Items]
Principal amount										250,000
Chulho Park [Member] | Fall 2019 Notes [Member] | Note Purchase Agreements [Member]
Debt Instrument [Line Items]
Due to related parties										27,000
Amit Shah [Member] | Fall 2019 Notes [Member] | Note Purchase Agreements [Member]
Debt Instrument [Line Items]
Due to related parties										20,000
Two Affiliates [Member] | Fall 2019 Notes [Member] | Note Purchase Agreements [Member]
Debt Instrument [Line Items]
Principal amount										$ 168,000
Silicon Valley Bank [Member] | Paycheck Protection Program Promissory Note [Member]
Debt Instrument [Line Items]
Principal amount								$ 250,000
Maturity date								Apr. 21, 2022
Debt interest rate								1.00%
Chief Executive Officer [Member] | Fall 2019 Notes [Member]
Debt Instrument [Line Items]
Due to related parties												70,000		70,000
Peak One and TFK Financing [Member]
Debt Instrument [Line Items]
Amortization expense related to debt discount														$ 262,556
Debt instrument, conversion description														All the above notes issued to Peak One, TFK, our CEO and the bridge investors reached the 180 days, TFK, our CEO and the bridge investors reached the 180 days prior to the end of the three months ended March 31, 2020. As such, all the note holders had the ability to convert that debt into equity at the variable conversion price of 65% of the Company's lowest traded price after the first 180 days or at the lower of the Fixed Price or 55% of the Company's traded stock price under certain circumstances.
Tranche One [Member] | Bridge Investor [Member] | Convertible Debt [Member] | Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Total unamortized debt discount												1,849		$ 1,849
Beneficial conversion feature, total														28,445
Percentage of conversion price, description						(i) a conversion price, during the first 180 days, of $0.10 per share (the "Fixed Price"), and then (2) at the lower of the Fixed Price or 65% of the Company's lowest traded price after the first 180 days or at the lower of the Fixed Price or 55% of the Company's traded stock price under certain circumstances. The Company may redeem the Convertible Note at rates of 110% to 140% rates over the principal balance dependent on certain events and redeem the value with accrued interest thereon, if any.
Principal amount					35,556	$ 35,556
Maturity date						Apr. 23, 2022
Original issue discount					$ 3,556	$ 3,556
Net proceeds from convertible debt						$ 32,000								888
Conversion price per share					$ 0.10	$ 0.10
Tranche One [Member] | Bridge Investor [Member] | Convertible Debt [Member] | Securities Purchase Agreement [Member] | Maximum [Member]
Debt Instrument [Line Items]
Percentage of charge on penalty						40.00%
Percentage of redemption of convertible note						140.00%
Tranche One [Member] | Bridge Investor [Member] | Convertible Debt [Member] | Securities Purchase Agreement [Member] | Minimum [Member]
Debt Instrument [Line Items]
Percentage of charge on penalty						18.00%
Percentage of redemption of convertible note						110.00%
Tranche 2 [Member] | Bridge Investor [Member] | Convertible Debt [Member] | Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Total unamortized debt discount												$ 15,396		15,396
Percentage of conversion price, description			(2) at the lower of the Fixed Price or 65% of the Company's lowest traded price after the first 180 days or at the lower of the Fixed Price or 55% of the Company's traded stock price under certain circumstances. The Company may redeem the Convertible Note at rates of 110% to 140% rates over the principal balance dependent on certain events and redeem the value with accrued interest thereon, if any.
Principal amount			$ 200,000
Maturity date			Aug. 6, 2022
Original issue discount			$ 20,000
Deferred financing costs			5,000
Net proceeds from convertible debt			$ 175,000											$ 157,779
Tranche 2 [Member] | Bridge Investor [Member] | Convertible Debt [Member] | Securities Purchase Agreement [Member] | Maximum [Member]
Debt Instrument [Line Items]
Percentage of charge on penalty			40.00%
Percentage of redemption of convertible note			140.00%
Tranche 2 [Member] | Bridge Investor [Member] | Convertible Debt [Member] | Securities Purchase Agreement [Member] | Minimum [Member]
Debt Instrument [Line Items]
Percentage of charge on penalty			18.00%
Percentage of redemption of convertible note			110.00%

Convertible Debentures. Notes_4

Convertible Debentures. Notes and Other Debt - Schedule of Convertible Debentures (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Short term debt from CEO	$ 70,000
Total of debentures, notes and other debt	1,348,542	$ 960,924
5% Convertible Note Payable - Stephen Boesch [Member]
Convertible note payable	250,648	187,785
5% Convertible Note Payable RelatedParty [Member]
Convertible note payable	250,477
5% Convertible Note Payable - Dr Sanjay Jha (Through His Family Trust) [Member]
Convertible note payable	249,997
5% Convertible Note Payable - CEO, CTO & CFO [Member]
Convertible note payable	84,268	77,620
5% Convertible Note Payable - Bridge Investors [Member]
Convertible note payable	172,647	159,025
5% Convertible Note Payable [Member]
Convertible note payable	1,008,037	800,000
5% Convertible Note Payable - Vuong Trieu [Member]
Convertible note payable		187,785
5% Convertible Note Payable - Sanjay Jha (Through His Family Trust) [Member]
Convertible note payable		187,785
10% Convertible Note Payable, Due June 12, 2022 [Member] | Peak One Opportunity Fund, L.P [Member]
Convertible note payable	11,183
10% Convertible Note Payable, Due April 23, 2022 [Member] | Bridge Investor [Member]
Convertible note payable	51,817	(2,748)
10% Convertible Note Payable, Due April 23, 2022 [Member] | Related Party [Member]
Convertible note payable	10,197	(12,663)
10% Convertible Note Payable, Due April 23, 2022 [Member] | Peak One Opportunity Fund, L.P [Member]
Convertible note payable		115,623
10% Convertible Note Payable, Due April 23, 2022 [Member] | TFK Investments, LLC [Member]
Convertible note payable	33,823	115,623
10% Convertible Note Payable, Due August 6, 2022 [Member] | Bridge Investor [Member]
Convertible note payable	163,485	26,824
10% Convertible Note Payable [Member]
Convertible note payable	$ 270,505	160,924
10% Convertible Note Payable, Due June 12, 2022 [Member] | Peak One Opportunity Fund, L.P [Member]
Convertible note payable		$ (81,735)

Convertible Debentures. Notes_5

Convertible Debentures. Notes and Other Debt - Schedule of Convertible Debentures (Details) (Parenthetical)	Sep. 30, 2020
5% Convertible Note Payable - Stephen Boesch [Member]
Interest rate	5.00%
5% Convertible Note Payable RelatedParty [Member]
Interest rate	5.00%
5% Convertible Note Payable - Dr Sanjay Jha (Through His Family Trust) [Member]
Interest rate	5.00%
5% Convertible Note Payable - CEO, CTO & CFO [Member]
Interest rate	5.00%
5% Convertible Note Payable - Bridge Investors [Member]
Interest rate	5.00%
10% Convertible Note Payable, Due June 12, 2022 [Member] | Peak One [Member]
Interest rate	10.00%
10% Convertible Note Payable, Due April 23, 2022 [Member] | Bridge Investor [Member]
Interest rate	10.00%
10% Convertible Note Payable, Due April 23, 2022 [Member] | Related Party [Member]
Interest rate	10.00%
10% Convertible Note Payable, Due April 23, 2022 [Member] | TFK Investments, LLC [Member]
Interest rate	10.00%
10% Convertible Note Payable, Due August 6, 2022 [Member] | Bridge Investor [Member]
Interest rate	10.00%

Private Placement and JH Darb_3

Private Placement and JH Darbie Financing (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Proceeds from private placement			$ 2,304,541
Warrant term	2 years 9 months		2 years 9 months
Issuance cost	$ 400,000
Legal costs	39,000
Non-controlling interests in Edgepoint	979,541
Initial debt discount	800,140		$ 800,140
Amortization of debt discount and debt issuance costs			611,681	88,479
Interest Expense [Member]
Amortization of debt discount and debt issuance costs	162,267		162,267
Convertible Debt Instrument [Member]
Initial debt discount	$ 60,000		$ 60,000
Maximum [Member]
Warrant term	5 years		5 years
Edgepoint Common Stock [Member] | Warrant [Member]
Warrants to purchase common stock	50,000		50,000
Warrant exercise price per share	$ 1		$ 1
Edgepoint Common Stock [Member] | One Convertible Promissory Note [Member]
Conversion of debt, price per share	$ 1		$ 1
Edgepoint Common Stock [Member] | One Convertible Promissory Note [Member] | Maximum [Member]
Conversion of debt, shares	25,000
Mateon Common Stock [Member] | Warrant [Member]
Warrants to purchase common stock	50,000		50,000
Warrant exercise price per share	$ 0.20		$ 0.20
Warrant term	3 years		3 years
Mateon Common Stock [Member] | One Convertible Promissory Note [Member]
Conversion of debt, price per share	$ 0.18		$ 0.18
Mateon Common Stock [Member] | One Convertible Promissory Note [Member] | Maximum [Member]
Conversion of debt, shares	138,889
Placement Agent [Member]
Number of shares issued and sold	5.3
Conversion of debt, price per share	$ 0.18		0.18
Percentage of units granted	10.00%
Debt instrument maturity term	Jun. 30, 2021
Debt instrument conversion term	Convertible at the option of the holder at any time in the Company's common stock or Edge Point's common share.
Coupon	16.00%
Placement Agent [Member] | Edgepoint Common Stock [Member]
Conversion of debt, price per share	$ 1		1
Subscription Agreements [Member] | Edgepoint Common Stock [Member]
Stock value, price per share	$ 1		1
Subscription Agreements [Member] | Edgepoint AI, Inc [Member]
Number of shares issued	25,000
Stock value, price per share	$ 1		$ 1
Subscription Agreements [Member] | Accredited Investors [Member]
Number of shares issued and sold	53
Proceeds from private placement	$ 2,650,000
Net of closing cost	$ 2,310,000

Private Placement and JH Darb_4

Private Placement and JH Darbie Financing - Schedule of Funds Received Under the Subscription Agreement (Details)	Sep. 30, 2020USD ($)
Convertible promissory notes	$ 1,000,000
Subscription Agreements [Member]
Convertible promissory notes	646,166
Subscription Agreements [Member] | Accredited Investors [Member]
Convertible promissory notes	612,892
Subscription Agreements [Member] | Related Party [Member]
Convertible promissory notes	$ 33,274

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Mar. 09, 2020	Apr. 23, 2019	Apr. 30, 2019	Jan. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Shares issued price per share					$ 0.18		$ 0.18
Common stock par value					$ 0.01		$ 0.01		$ 0.01
Chief Executive Officer [Member]
Payments of related party debt							$ 70,000
Shares issued during the period for private placing, shares							3
Shares issued during the period for private placing							$ 150,000
Chief Executive Officer [Member] | Fall 2019 Note [Member]
Principal amount			$ 250,000
Debt conversion amount			35,000
Autotelic Inc., [Member]
Shares issued price per share				$ 4
Master Service Agreement [Member] | Autotelic Inc., [Member]
Agreement related expenses					$ 6,011	$ 309,194	$ 291,887	$ 1,004,315
Number of shares issued during the period				80,772
Shares issued price per share				$ 4
Master Service Agreement [Member] | Autotelic Inc., [Member] | Vuong Trieu [Member]
Termination agreement, description							The MSA requires a 90-day written termination notice in the event either party requires to terminate such services.
Master Service Agreement [Member] | Autotelic Inc., [Member] | Vuong Trieu [Member] | Maximum [Member]
Equity ownership percentage					10.00%		10.00%
Securities Purchase Agreement [Member] | Vuong Trieu [Member] | Convertible Debt [Member]
Principal amount		$ 164,444	164,444
Original issue discount		16,444	$ 16,444
Net proceeds from convertible debt		$ 148,000
Artius Consulting Agreement [Member] | Board of Directors [Member] | 2017 Equity Incentive Plan [Member]
Equity ownership percentage	30.00%
Termination agreement, description	Either the Company or Artius may terminate the Artius Agreement at any time, for any reason following the Effective Date. The Artius Agreement will automatically renew one year from the Artius Agreement Effective Date, unless the Parties agree to terminate the Artius Agreement at that time.
Agreement related expenses							$ 106,712
Number of restricted shares	148,837
Debt description	The Artius Agreement contemplates that Mr. King will generally provide his services at a rate of $237 per hour, not to exceed 44 hours per month and payable monthly, and to reimburse Mr. King for reasonable and necessary expenses incurred by him or Artius in connection with providing services to the Company.
Maida Consulting Agreement [Member] | Dr. Maida [Member]
Termination agreement, description							Either the Company or Dr. Maida may terminate the Maida Agreement, for any reason, upon 30 days advance written notice.
Agreement related expenses					$ 45,000		$ 90,000
Number of restricted shares							400,000
Common stock par value					$ 0.20		$ 0.20
Debt description							The Company will also pay Dr. Maida $15,000 per month for a minimum of 20 hours per week, in in addition to reimbursement of reasonable and necessary expenses incurred by Dr. Maida in connection with his services to the Company.
Number of restricted shares, shares							$ 80,000
Vested date							May 5, 2021
Healthcare Insurance [Member] | Autotelic Inc., [Member]
Reimbursement of expense							$ 261,246

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)

1 Months Ended

3 Months Ended

Jul. 31, 2020

Jun. 30, 2020

Mar. 31, 2020

Feb. 29, 2020

Nov. 30, 2019

Jun. 30, 2019

Apr. 30, 2019

Mar. 31, 2019

Jan. 31, 2019

Jun. 30, 2019

Mar. 31, 2019

Sep. 30, 2020

Shares issued price per share

$ 0.18

Number of shares issued during the period, value

$ 83,000

Common shares issued in conversion of warrants

$ 120

Merger Agreement [Member]

Common shares issued for settlement of accounts payable

10,318,746

Merger Agreement [Member] | Convertible Debt [Member]

Number of restricted stock issued during the period

350,000

Two Investors [Member]

Common shares issued in conversion of warrants

$ 150,000

Common shares issued in conversion of warrants, shares

120

Two Noteholders [Member] | Merger Agreement [Member] | Convertible Debt [Member]

Shares issued price per share

$ 0.18

$ 0.11

$ 0.18

Number of restricted stock issued during the period

700,000

Oncotelic [Member] | Merger Agreement [Member]

Common shares issued for settlement of accounts payable

41,000,033

Oncotelic [Member] | Merger Agreement [Member] | Series A Preferred Stock [Member]

Common shares issued for settlement of accounts payable

193,713

Number of shares issued during the period

77,154

Oncotelic [Member] | Employee [Member]

Common shares issued for compensation

$ 80,594

$ 11,250

Shares issued price per share

$ 4

$ 4

$ 4

Oncotelic [Member] | Two Separates Investors [Member]

Shares issued price per share

$ 4

Number of shares issued during the period

20,750

Number of shares issued during the period, value

$ 83,000

Autotelic Inc., [Member]

Shares issued price per share

$ 4

Common shares issued for settlement of accounts payable

80,772

PointR [Member] | Merger Agreement [Member] | Series A Preferred Stock [Member]

Common shares issued for settlement of accounts payable

11,135,935

Number of shares issued during the period

84,475

Peak One [Member]

Number of shares issued during the period

500,000

500,000

Peak One [Member] | Convertible Notes Payable [Member]

Number of shares issued during the period

569,800

1,200,000

Peak One [Member] | Convertible Notes Payable [Member] | Traunche Two [Member]

Number of shares issued during the period

1,000,000

TFK Investments, LLC [Member]

Number of shares issued during the period

750,000

TFK Investments, LLC [Member] | Restricted Shares [Member]

Shares issued price per share

$ 0.20

Number of shares issued during the period

300,000

Number of shares issued during the period, value

$ 60,000

Conversion percentage

65.00%

Conversion maturity date

Jan. 8, 2020

Conversion price per share

$ 0.10

TFK Investments, LLC [Member] | Convertible Notes Payable [Member]

Number of shares issued during the period

1,012,145

Peak One Opportunity Fund, L.P [Member] | Restricted Shares [Member]

Shares issued price per share

$ 0.20

0.20

Number of shares issued during the period

300,000

Number of shares issued during the period, value

$ 60,000

Conversion percentage

65.00%

Conversion maturity date

Jan. 18, 2020

Conversion price per share

$ 0.10

$ 0.10

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended			9 Months Ended		12 Months Ended
	Feb. 29, 2020	Apr. 30, 2019	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Options exercisable term						10 years
Options vesting period						3 years
Aggregate intrinsic value of options			$ 0			$ 0
Weighted average fair value						$ 0.18
Share based compensation		$ 341,000		$ 2,100,000
Number of share-based payment award, accelerated vesting		328,000
Reissuance of warrants	13,750,000
Warrants excersiable term			2 years 9 months			2 years 9 months
Number of warrants issued during period				13,750,000
Warrants issued			18,152,500			18,152,500
Initial debt discount			$ 800,140			$ 800,140
Amortization of debt discount and debt issuance costs						611,681	$ 88,479
Interest Expense [Member]
Amortization of debt discount and debt issuance costs			162,267			162,267
Convertible Debt Instrument [Member]
Initial debt discount			$ 60,000			$ 60,000
Private Placement [Member]
Weighted average fair value			$ 0.20
Warrant exercise price per share			0.20			$ 0.20
Private Placement [Member] | Edgepoint Common Stock [Member]
Warrant exercise price per share			$ 1			$ 1
Accredited Investors [Member]
Warrants issued				2,915,000
Maximum [Member]
Warrants excersiable term			5 years			5 years
Maximum [Member] | Private Placement [Member]
Number of common stock issued to awards			2,915,000
Additional paid-in capital on a relative fair value basis			$ 400,000
Minimum [Member]
Warrants excersiable term			3 years			3 years
2017 Equity Incentive Plan [Member] | Maximum [Member]
Number of common stock issued to awards						2,000,000
2015 and 2005 Equity Incentive Plan [Member] | Maximum [Member]
Number of common stock issued to awards						7,250,000

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Compensation Based Stock Option Activity (Details)	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Compensation Related Costs [Abstract]
Options Outstanding, Beginning Balance | shares	6,145,044
Options Outstanding, Expired or canceled | shares	(15,040)
Options Outstanding, Ending Balance | shares	6,130,004
Weighted Average Exercise Price Outstanding, Beginning Balance | $ / shares	$ 0.75
Weighted Average Exercise Price, Expired or canceled | $ / shares	2.72
Weighted Average Exercise Price Outstanding, Ending Balance | $ / shares	$ 0.75

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Options to Purchase Shares of Common Stock Outstanding and Exercisable (Details)	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Number of Outstanding Options	6,130,004
Weighted Average Remaining Life In Years	6 years 5 months 27 days
Weighted-Average Exercise Price | $ / shares	$ 0.75
Number Exercisable	6,130,004
Exercise Price One [Member]
Exercise Prices | $ / shares	$ 0.22
Number of Outstanding Options	2,524,513
Weighted Average Remaining Life In Years	7 years 8 months 23 days
Weighted-Average Exercise Price | $ / shares	$ 0.22
Number Exercisable	2,524,513
Exercise Price Two [Member]
Exercise Prices | $ / shares	$ 0.38
Number of Outstanding Options	1,162,500
Weighted Average Remaining Life In Years	6 years 3 months 15 days
Weighted-Average Exercise Price | $ / shares	$ 0.38
Number Exercisable	1,162,500
Exercise Price Three [Member]
Exercise Prices | $ / shares	$ 0.51
Number of Outstanding Options	242,966
Weighted Average Remaining Life In Years	6 years 8 months 12 days
Weighted-Average Exercise Price | $ / shares	$ 0.51
Number Exercisable	242,966
Exercise Price Four [Member]
Exercise Prices | $ / shares	$ 0.58
Number of Outstanding Options	271,224
Weighted Average Remaining Life In Years	6 years 26 days
Weighted-Average Exercise Price | $ / shares	$ 0.58
Number Exercisable	271,224
Exercise Price Five [Member]
Exercise Prices | $ / shares	$ 0.73
Number of Outstanding Options	1,025,000
Weighted Average Remaining Life In Years	5 years 5 months 23 days
Weighted-Average Exercise Price | $ / shares	$ 0.73
Number Exercisable	1,025,000
Exercise Price Six [Member]
Exercise Prices | $ / shares	$ 1.37
Number of Outstanding Options	150,000
Weighted Average Remaining Life In Years	4 years 9 months 22 days
Weighted-Average Exercise Price | $ / shares	$ 1.37
Number Exercisable	150,000
Exercise Price Seven [Member]
Exercise Prices | $ / shares	$ 1.43
Number of Outstanding Options	525,000
Weighted Average Remaining Life In Years	4 years 7 months 28 days
Weighted-Average Exercise Price | $ / shares	$ 1.43
Number Exercisable	525,000
Exercise Price Nine [Member]
Exercise Prices | $ / shares	$ 2.95
Number of Outstanding Options	150,000
Weighted Average Remaining Life In Years	3 years 7 months 13 days
Weighted-Average Exercise Price | $ / shares	$ 2.95
Number Exercisable	150,000
Exercise Price Ten [Member]
Exercise Prices | $ / shares	$ 11.88
Number of Outstanding Options	2,359
Weighted Average Remaining Life In Years	1 year 3 months 4 days
Weighted-Average Exercise Price | $ / shares	$ 11.88
Number Exercisable	2,359
Exercise Price Eleven [Member]
Exercise Prices | $ / shares	$ 15
Number of Outstanding Options	75,000
Weighted Average Remaining Life In Years	4 years 7 months 28 days
Weighted-Average Exercise Price | $ / shares	$ 15
Number Exercisable	75,000
Exercise Price Twelve [Member]
Exercise Prices | $ / shares	$ 19.80
Number of Outstanding Options	1,442
Weighted Average Remaining Life In Years	1 year 29 days
Weighted-Average Exercise Price | $ / shares	$ 19.80
Number Exercisable	1,442

Stock-Based Compensation - Sc_3

Stock-Based Compensation - Schedule of Warrants Activity (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Compensation Related Costs [Abstract]
Number of Stock Options Outstanding, beginning balance	19,515,787	24,380,893
Number of Stock Options, Issued	16,665,000
Number of Stock Options, Expired or cancelled	(18,028,287)	(4,865,106)
Number of Stock Options Outstanding, ending balance	18,152,500	19,515,787
Weighted-Average Exercise Price, Outstanding, beginning balance	$ 0.60	$ 1.05
Weighted-Average Exercise Price, Issued	0.20
Weighted-Average Exercise Price, Expired or cancelled	0.63	2.82
Weighted-Average Exercise Price, Outstanding, ending balance	$ 0.20	$ 0.60

Stock-Based Compensation - Sc_4

Stock-Based Compensation - Schedule of Warrants Outstanding and Exercisable (Details)	Sep. 30, 2020$ / sharesshares
Warrants Outstanding, Number of Warrants	18,152,500
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 9 months
Warrants Weighted- Average Exercise Price | $ / shares	$ 0.20
Warrants Exercisable, Exercisable Number of Warrants	15,237,500
Exercise Price One [Member] | Warrant [Member]
Warrants Outstanding, Exercise Price | $ / shares	$ 0.20
Warrants Outstanding, Number of Warrants	1,487,500
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 9 months
Warrants Weighted- Average Exercise Price | $ / shares	$ 0.20
Warrants Exercisable, Exercisable Number of Warrants	1,487,500
Exercise Price Two [Member] | Warrant [Member]
Warrants Outstanding, Exercise Price | $ / shares	$ 0.20
Warrants Outstanding, Number of Warrants	2,915,000
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years
Warrants Weighted- Average Exercise Price | $ / shares	$ 0.20
Warrants Exercisable, Exercisable Number of Warrants
Exercise Price Three [Member] | Warrant [Member]
Warrants Outstanding, Exercise Price | $ / shares	$ 0.20
Warrants Outstanding, Number of Warrants	13,750,000
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 9 months
Warrants Weighted- Average Exercise Price | $ / shares	$ 0.20
Warrants Exercisable, Exercisable Number of Warrants	13,750,000

Stock-Based Compensation - Sc_5

Stock-Based Compensation - Schedule of Black Scholes Valuation Allowance Model of Warrants (Details) - Warrant [Member]	9 Months Ended
	Sep. 30, 2020
Expected Term	3 years
Expected volatility	140.50%
Risk-free interest rates	1.40%
Dividend yields	0.00%
Private Placement [Member]
Expected Term	1 year 6 months
Dividend yields	0.00%
Private Placement [Member] | Minimum [Member]
Expected volatility	184.70%
Risk-free interest rates	0.13%
Private Placement [Member] | Maximum [Member]
Expected volatility	191.90%
Risk-free interest rates	0.15%

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Gross deferred tax assets	$ 66,100,000	$ 65,000,000
Net operating loss carry-forwards	$ 3,700,000	$ 248,000,000
Net operating loss expiration year	2038
Federal Income Tax [Member]
Net operating loss carry-forwards	$ 251,700,000

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative) - USD ($)	1 Months Ended
	Aug. 31, 2019	Sep. 30, 2020
Contingent liability		$ 2,600,000
Merger Agreement [Member] | PointR Data, Inc [Member]
Purchase price consideration	$ 17,831,427
Contingent liability	$ 2,625,000

Commitments and Contingencies -

Commitments and Contingencies - Summary of Restricted Stock Grants and Stock Option Grants (Details)	9 Months Ended
	Sep. 30, 2020shares
Vuong Trieu [Member] | Chief Executive Officer [Member]
Restricted Stock	209,302
Stock Options	313,953
Chulho Park [Member] | Chief Technology Officer [Member]
Restricted Stock	162,791
Stock Options	244,186
Amit Shah [Member] | Chief Financial Officer [Member]
Restricted Stock	148,837
Stock Options	223,256

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Oct. 30, 2020	Jun. 30, 2020	Sep. 30, 2020	Jun. 25, 2020	Jun. 24, 2020	Dec. 31, 2019
Subsequent Event [Line Items]
Common stock, shares authorized			150,000,000			150,000,000
Common Stock [Member] | Restated 2015 Equity Incentive Plan [Member]
Subsequent Event [Line Items]
Number of common shares available for issuance				27,250,000	7,250,000
Increasing the maximum number of stock awards				1,000,000	500,000
Common stock, shares authorized				750,000,000	150,000,000
GMP Note [Member]
Subsequent Event [Line Items]
Secured debt		$ 2,000,000
Convertible note term		1 year
Debt instrument interest		2.00%
Debt instrument description		In June 2020, Mateon secured $2 million in debt financing, evidenced by a one year convertible note (the "GMP Note") from GMP, to conduct a clinical trial evaluating OT-101 against COVID-19 bearing 2% annual interest, and is personally guaranteed by Dr. Vuong Trieu, the Chief Executive Officer of Mateon.
GMP Note [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Cash paid to clinical trial organization	$ 500,000